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1. Introduction 
Myocardial ischemia, or lack of oxygen, is caused by an imbalance between oxygen supply 
and oxygen demand in the heart. This imbalance is usually due to an inability to increase 
coronary blood flow in response to increased myocardial oxygen consumption. The inability 
to increase coronary blood flow is often related to atherosclerosis of the large coronary 
arteries, which leads to a progressive narrowing of the blood vessel lumen and a reduction 
in coronary blood flow. Coronary blood flow may also be restricted by either focal or 
generalized intense vasoconstriction (i.e. vasospasm) in the major coronary arteries. 
Antianginal drugs may effectively relieve or prevent acute ischemic episodes by increasing 
myocardial oxygen supply, decreasing myocardial oxygen demand, or both. 
2. Conventional antianginal 
2.1 Nitrates (short and long acting) and nitrites 
Sir Thomas Lauder Brunton first used amyl nitrite in the treatment of angina pectoris in 
1867. As a medical student, Brunton had became aware of prior clinical findings of Benjamin 
Ward Richardson that inhaled amyl nitrite rapidly increased the action of the heart 
(Richardson, 1864), and also the unpublished observations of Arthur Gamgee demonstrating 
that amyl nitrite greatly lessened ‘arterial tension’ in both animals and man (Brunton, 1867). 
At the same time William Murrell, began using the organic nitrate; glyceryl trinitrate 
(GTN), in the treatment of angina pectoris (Murrell, 1879). With GTN therapy, patients 
would obtain relief from angina with some patients also reporting that their angina could be 
aborted by taking the drug at the onset of symptoms. In the 1920s, Richard Bodo used the 
Starling’s heart–lung preparation to determine the effects of two nitrite preparations on 
coronary flow (Bodo, 1928) as earlier work in myocardial studies demonstrated that nitrite 
preparations produced vasorelaxation (Francois-Frank, 1903; Schloss, 1913; Cow, 1910). By 
the 1930s, nitrites and nitrate esters were established treatments for angina and 
hypertension. Contro and colleagues observed a paradoxical action following inhalation of 
amyl nitrite in patients with coronary artery disease, in that electrocardiograph changes 
resembling myocardial ischemia would occur after administration of amyl nitrite due to a 
sudden drop in blood pressure followed by coronary insufficiency (Contro et al., 1952). 
Finally, the authors suggested that the nitrite could be used as a diagnostic test in patients 
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with borderline or questionable history of coronary artery disease. The nitrites/nitrates are 
classified as agents that directly relax vascular smooth muscle, but can also relax other 
smooth muscles such as bronchial, ureteral, and uterine smooth muscle (Chen et al., 2001; 
Dong et al., 1998; Facchinetti et al., 1996; Yallampalli et al., 1993). 
2.1.1 Mechanisms of action  
It is generally believed that the therapeutic effect of these drugs involves the release of nitric 
oxide (NO) from nitrite, the activation of guanylyl cyclase, and relaxation of blood vessels. 
Interactions with nitroglycerin (GTN) and sulfhydryl-containing receptors are necessary for 
vascular smooth muscle relaxation and repeated administration of GTN produces 
sulfhydryl depletion and the development of tolerance. Subsequent studies have 
demonstrated the release of NO following the decomposition of an intermediate S-
nitrosothiol. Additional studies suggest that an enzymatic mechanism may be responsible 
for the bio-activation of GTN. 
2.1.2 Cardiovascular pharmacological effects 
The most commonly nitrites and nitrates agents at this time include isosorbide dinitrate, 
isosorbide-5-mononitrate, and GTN which are effective in reducing ventricular preload by 
increasing peripheral venous capacitance. These drugs can also decrease pulmonary and 
systemic vascular resistances, but require higher doses than those needed for the increase in 
venous capacitance. These agents can reduce ventricular filling pressure, wall stress and 
myocardial oxygen consumption, and may also improve systolic and diastolic ventricular 
function by improving coronary flow in patients with ischemic cardiomyopathy. However, 
there is, as yet, no convincing evidence that organic nitrates improve mortality in patients 
with acute myocardial infarction. The limitations of this class of agents are well known and 
potentially include adverse hemodynamic effects, drug tolerance, lack of selectivity, and 
limited bioavailability. Nitrates are recommended by the ACC/AHA guidelines as part of 
the initial management of ST elevation myocardial infarction (STEMI) and unstable angina 
(UA)/non-ST elevation myocardial infarction (NSTEMI). Nitrates can provide symptomatic 
relief in acute coronary syndrome (ACS) but are not associated with a survival benefit in 
younger ACS patients. However, nitrate use in the elderly ACS patients is associated with a 
reduction in mortality, heart failure, and left ventricular dysfunction at 6 months follow-up. 
The antianginal properties of nitrates can be attributed to the augmentation of coronary flow 
and to the decrease in the heart’s oxygen consumption that they cause. Nitrates induce 
coronary vasodilatation, leading to better myocardial perfusion. They also produce 
venodilatation, leading to decreased venous return, and thus to reduced cardiac preload. 
Glyceryl trinitrate also exerts antiplatelet effects in patients with stable angina pectoris. 
Short-acting GTN is used sublingually to relieve symptoms of angina. Long-acting nitrates 
can be used in combination with a beta blocker if monotherapy has proven unsuccessful or 
in combination with calcium channel antagonist if beta blockade leads to unacceptable 
adverse drug reactions. During exercise, nitrates increase the delay before the onset of 
angina and the time to 1 mm ST segment depression (TST), but their effects are improved 
when used in combination with another antianginal agent. Nitrates should be administered 
intermittently, with 8 to 12 hours of nitrate-free intervals, to prevent pharmacologic 
tolerance. However, a rebound phenomenon with anginal symptoms is possible during 
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these intervals. Short acting nitrates control angina most effectively when administered in 
the morning. In contrast, long acting nitrates are designed for once per day dosing and 
should normally be administered at bedtime to maintain a therapeutic concentration in the 
plasma throughout the night and the subsequent vulnerable morning hours. The most 
frequent side effect of nitrates is headache, reported by up to 82% of patients in placebo-
controlled trials in a dose-related fashion, with about 10% of patients reporting severe 
symptoms leading to discontinuation of the treatment (Thadani & Rodgers, 2006). 
Hypotension is frequent and usually asymptomatic, although syncope can rarely occur. The 
tolerance phenomenon associated with the chronic use of long-acting nitrates imposes the 
need for an 8–12 hour nitrate-free interval every day, which can occasionally lead to angina 
attacks at night during this period. Nitrates are contraindicated in patients with severe 
aortic stenosis or hypertrophic obstructive cardiomyopathy. Furthermore, concomitant use 
of nitrates and sildenafil can provoke severe potentially life-threatening hypotension, 
making this combination an absolute contraindication. Indeed, patients should be warned 
never to use sildenafil within 24 hours of nitrate consumption. 
2.2 β-adrenoceptor blockers 
ǃ-blockers differ in physicochemical, pharmacokinetic and pharmacodynamic properties. 
Current drugs vary in their selectivity for ǃ1-, ǃ2- and ǃ3-adrenoceptors, and some, such as 
carvedilol and labetalol, are also ǂ1-adrenoceptor antagonists. Some have partial agonist 
activity or intrinsic sympathetic activity (ISA), local anaesthetic properties (membrane-
stabilising activity), potassium (K+) channel blocking activity or antioxidant properties. The 
number of ǃ-blockers available rapidly increased and became the major first-line therapy for 
hypertension. Improvements in the symptomatic management of angina were followed by 
improvements in mortality in acute myocardial infarction and long-term when given post-
myocardial infarction. ǃ-blockers also reduce arrhythmias after both cardiac and non-
cardiac surgery. Thus, ǃ-blockers now have important role in improving both mortality and 
symptom control in ischaemic heart disease, arrhythmias and hypertension (Table 1) 
(Hollenberg, 2005). In patients with stable angina who also manifest congestive heart failure 
symptoms with reduced left systolic function, ǃ‐blockers are particularly beneficial and 
reduce heart failure related mortality by approximately 35% (Klein et al., 2003). 
2.2.1 Properties of β-blockers 
1. Subtype selectivity. The prototypical ǃ-blocker propranolol has similar affinity for ǃ1- 
and ǃ2- adrenoceptors and lower affinity for ǃ3-adrenoceptors. However, even the 
‘cardioselective’ ǃ-blockers, a nomenclature based on their selectivity for ǃ1-
adrenoceptors, are not, because none in clinical use are that selective (13-fold at most) 
(Baker, 2005; Schnabel, 2000). Although bisoprolol and nebivolol are the most ǃ1-
selective and carvedilol having slight ǃ2-selectivity, it is not possible to predict what 
level of selectivity. Most currently available ǃ-blockers (including propranolol) have 
low affinity for the ǃ3-adrenoceptor. There are, however, a subset of drugs comprising 
oxprenolol, carazolol, pindolol, nadolol, tertatolol, carteolol, arotinolol and nebivolol 
that have agonist effects at the ǃ3-adrenoceptor that could be responsible for the nitric 
oxide (NO)-mediated vasodilator properties observed with nebivolol (Baker, 2010). 
Even SR59230A, claimed to be selective for ǃ3-adrenoceptors, has a similar potency at 
all 3 subtypes (Baker, 2010, Michel, 2010). 
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2. Intrinsic sympathomimetic activity (ISA) and partial agonism. Some ǃ-blockers are 
traditionally described as having ISA (Table 2). These drugs block the stimulatory 
effects of high-efficacy agonists, such as catecholamines, but stimulate agonist 
responses of their own. This is evident at both the cellular and tissue level with 
acebutolol, carteolol, penbutolol, pindolol, bucindolol and xamoterol, for which it is 
claimed that bradycardia and bronchoconstriction are less than for other ǃ-
adrenoceptor antagonists. However, drugs with ISA are less advantageous in the 
management of heart failure and migraine. 
3. Low-affinity state of the ǃ1-adrenoceptor. Some ǃ-adrenoceptor antagonists stimulate 
ǃ1-adrenoceptor function by interacting with a low-affinity state of the ǃ1-adrenoceptor 
(Molenaar, 2003) and the ǃ3-adrenoceptor (Baker, 2003). Activation of this low-affinity 
state of the ǃ1-adrenoceptor has been demonstrated in whole animals (Cohen, 2000) and 
humans (Kaumann and Molenaar, 1997). ǃ-adrenoceptor antagonists with similar 
properties include oxprenolol, alprenolol, carazolol, pindolol and carvedilol. These 
ligands either stimulate agonist responses at concentrations much higher than those 
required to fully occupy and block the conventional catecholamine ǃ1-adrenoceptor site, 
or have biphasic concentration–response curves. However, there is currently no 
therapeutic use for this property of ǃ-adrenoceptor antagonists. 
4. Inverse agonism. Many ǃ-adrenoceptor antagonists, at least at the ǃ2-adrenoceptor, are 
in fact inverse agonists (i.e. rather than just occupying the binding site and thus 
blocking the actions of agonists, they are associated with conformations of the receptor 
that turn off signalling) (Swaminath, 2005). 
5. Other properties of ǃ-blockers. Local anaesthetic or membrane-stabilising activity is 
shown by some ǃ-adrenoceptor antagonists, notably propranolol and acebutolol and to 
a lesser extent pindolol and labetalol. This property is unlikely to be important in the 
therapeutic effects of ǃ-blockers because it occurs at much higher concentrations than 
those normally encountered clinically. Individual (rather than class effect) properties of 
certain ǃ-blockers include lipophilicity, K+ channel blockade and antioxidant properties. 
Propranolol, timolol and metoprolol are somewhat lipophilic. Sotalol can block K+ 
channels independently of its ǃ-blocking properties. Carvedilol blocks ǂ1- and ǃ-
adrenoceptors, inhibits apoptosis and possesses antioxidant and free-radical-
scavenging actions. Nebivolol causes NO-dependent vasodilation. These properties 
might contribute to their efficacy in cardiac failure. 
2.2.2 Hemodynamic effects of β-blockers 
ǃ-adrenoceptor antagonists competitively inhibit the binding of endogenous catecholamines 
to ǃ1-adrenoceptors in the heart and most evidence strongly suggests that their anti-ischemic 
effects are due to cardiac depression. Myocardial oxygen demand is determined in large part 
by heart rate and cardiac contractility. Increased heart rate and contractility result in 
increased myocardial oxygen consumption and, conversely, reductions in heart rate and 
contractility lead to a decrease in oxygen consumption. By inhibiting the actions of 
norepinephrine and epinephrine on the heart, the ǃ-adrenoceptor antagonists exert their 
negative dromotropic and intropic effects, and thereby attenuate the myocardial response to 
sympathetic nervous system stimulation that occurs, for example, with increased stress or 
exercise. Though most ǃ-adrenoceptor antagonists lower resting heart rate to some extent, 
the effect on exercise-induced tachycardia is much more pronounced. Thus, for a given 
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degree of physical activity, myocardial oxygen consumption is diminished. It is important to 
note that the ǃ-adrenoceptor antagonists do not change the point of imbalance between 
myocardial oxygen supply and consumption at which angina occurs; rather, they reduce the 
likelihood that this point is reached. By mechanisms that remain poorly understood, ǃ-
adrenoceptor antagonists also decrease peripheral vascular resistance, which leads to a 
reduction in arterial blood pressure and afterload (Hoffman, 2007). Reduced afterload 
results in decreased left ventricular wall tension, which is another major determinant of 
myocardial oxygen demand. This beneficial effect of the ǃ-adrenoceptor antagonists may be 
partially offset, however, by an increase in left ventricular end-diastolic volume that occurs 
due to increased cardiac filling during diastole, but the net effect is to lessen oxygen 
demand. On the other hand myocardial oxygen supply is a function of both oxygen delivery 
(the heart is almost exclusively dependent on aerobic metabolism and an adequate supply of 
oxygen is critical to sustained cardiac activity) and oxygen extraction from the blood. Since 
oxygen extraction from coronary blood is near maximal at rest, there is little reserve to meet 
increased demand due to increased cardiac activity (Tune et al., 2004). Thus, the most 
important determinant of myocardial oxygen supply is total coronary blood flow. ǃ-
adrenoceptor antagonists have little propensity to increase coronary blood flow and 
myocardial oxygen supply, in fact ǃ-adrenoceptor antagonists may increase coronary 
vascular resistance by inhibiting the ǃ2-adrenoceptor-mediated vasodilator effects of 
endogenous catecholamines and leaving ǂ-adrenoceptor-mediated vasoconstriction 
unopposed. Thus, the anti-ischemic effects of the ǃ-adrenoceptor antagonists are largely due 
to their ability to reduce myocardial workload and decrease oxygen consumption, rather 
than to improve myocardial oxygen supply. 
Propranolol Hypertension, ischaemic heart disease, arrhythmias, portal hypertension, 
anxiety, essential tremor, migraine, thyrotoxicosis 
Acebutolol Hypertension, ischaemic heart disease, arrhythmias 
Atenolol Hypertension, ischaemic heart disease, arrhythmias, migraine 
Betaxolol Glaucoma 
Bisoprolol Hypertension, ischaemic heart disease, heart failure 
Carteolol Glaucoma 
Carvedilol Hypertension, ischaemic heart disease, heart failure 
Celiprolol Hypertension 
Esmolol Arrhythmias (short-term) 
Labetolol Hypertension 
Levobunolol Glaucoma 
Metipranolol Glaucoma 
Metoprolol Hypertension, ischaemic heart disease, arrhythmias, migraine 
Nadolol Hypertension, ischaemic heart disease, arrhythmias, migraine, thyrotoxicosis 
Nebivolol Hypertension, heart failure 
Oxprenolol Hypertension, ischaemic heart disease, arrhythmias, anxiety 
Pindolol Hypertension, ischaemic heart disease 
Sotalol Arrhythmias 
Timolol Glaucoma, hypertension, ischaemic heart disease, migraine 
Table 1. Current indications for ǃ-blockers from the British National Formulary September 
2010 (www.bnf.org) 
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Generation Drugs Specifications 
First Propranolol, Timolol Non-cardioselective 
Second Metoprolol 
Atenolol, Bisoprolol,  
Betaxolol 
Cardioselective, short acting 
Cardioselective, sustained release 
 
Third Labetalol 
 
 
 
Carvedilol 
 
 
 
 
Nebivolol 
 
Non-cardioselective, vasodilation (Higher 
affinity for ǂ1 receptor (ǂ1 receptor blockade) 
than ǃ1 and ǃ2) 
 
Cardioselective, vasodilation (ǃ1 selective, 
decerased selectivity at higher doses, ǂ1 
receptor blockade, increases insulin sensitivity, 
antioxidant properties) 
 
Cardioselective, vasodilation (Higher ǃ1 
selectivity; endothelium‐dependent 
vasodilation via the L‐arginine/nitric oxide 
pathway) 
 
Table 2. Classification of beta blockers that used for treatment of chronic stable angina 
2.2.3 Clinical application of β-blockers in angina  
ǃ-adrenoceptor antagonists are a mainstay in the treatment of chronic stable angina. While 
coronary blood flow (i.e. oxygen supply) may be sufficient to meet myocardial oxygen 
requirements at rest in patients with fixed atherosclerotic lesions, the obstruction prevents 
blood flow from increasing during periods of increased oxygen demand. Under these 
conditions coronary blood flow is already at a maximal level in most patients, thus any 
increase in myocardial work can trigger an episode of acute angina. Precipitating factors 
include physical exertion, emotional stress or excitement, and temperature extremes. By 
decreasing heart rate, myocardial contractility, and afterload, ǃ-adrenoceptor antagonists 
reduce myocardial workload and oxygen consumption at rest as well as during periods of 
exertion or stress. Oral ǃ-adrenoceptor antagonists are widely used in long-term 
maintenance therapy to prevent acute ischemic episodes. Prophylactic use of these agents 
reduces the frequency and severity of acute anginal attacks. Because of their slow onset of 
action, oral ǃ-adrenoceptor antagonists are not appropriate for terminating an acute attack 
of angina once it has begun; sublingual nitroglycerin is the agent most frequently used 
under these conditions. Several ǃ-adrenoceptor antagonists, including propranolol, 
metoprolol, and atenolol, have cardioprotective effects and have been shown to decrease 
mortality after myocardial infarction (Bunch et al., 2005). In patients with variant 
(Prinzmetal's) angina, the major underlying cause of angina is vasospasm of one or more 
coronary arteries. Intense vasoconstriction decreases coronary blood flow, thereby reducing 
myocardial oxygen supply. Coronary vasospasm can occur in arteries with little or no 
atherosclerotic plaque and is not associated with an increase in myocardial oxygen demand. 
Indeed, variant angina may strike at any time of the day or night, including during periods 
of rest or sleep. In contrast to stable angina, variant angina is most often the result of an 
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abrupt decrease in myocardial oxygen supply (i.e. coronary blood flow) rather than an 
increase in myocardial oxygen demand. Unlike nitrates and calcium channel blockers, ǃ-
adrenoceptor antagonists do not directly dilate coronary arteries to increase coronary blood 
flow. Moreover, blockade of vascular ǃ-adrenoceptors inhibits the vasodilator actions of 
endogenous catecholamines and may exacerbate ǂ-adrenoceptor-mediated vasoconstriction 
in coronary arteries. Thus, ǃ-adrenoceptor antagonists may worsen coronary vasospasm and 
are not indicated for treatment of vasospastic angina. ǃ-adrenoceptor antagonists may 
reduce the risk of progression to acute myocardial infarction in patients with unstable 
angina (Braunwald et al., 2002).The pathophysiology of this condition is often complex and 
may involve several underlying factors superimposed upon one another, including rupture 
of atherosclerotic plaques and thrombus formation, constriction of coronary arteries, and 
increased myocardial oxygen demand. In these patients, the beneficial effects of the ǃ-
adrenoceptor antagonists are likely due to a reduction in myocardial oxygen consumption. If 
coronary vasospasm is the major underlying problem, nitrates or calcium channel blockers 
would be more effective and ǃ-adrenoceptor antagonists should be used with caution. When 
used concurrently, ǃ-adrenoceptor antagonists can inhibit the baroreceptor-mediated reflex 
tachycardia and positive inotropic effects that may sometimes occur with organic nitrates. 
Alternatively, organic nitrates increase venous capacitance and can thereby offset ǃ-
adrenoceptor antagonist-mediated increases in left ventricular end-diastolic volume. 
Moreover, organic nitrates are coronary vasodilators and, as such, may prevent the increase 
in coronary vasomotor tone that may potentially result from blockade of vascular ǃ-
adrenoceptors. Dihydropyridine calcium channel blockers are also potent coronary 
vasodilators and provide similar advantages with regard to coronary vascular resistance in 
patients treated simultaneously with ǃ-adrenoceptor antagonists. As with nitrates, 
dihydropyridines may also cause reflex tachycardia that can be alleviated by ǃ-adrenoceptor 
antagonists. Concurrent use of ǃ-adrenoceptor antagonists with the non-dihydropyridine 
calcium channel blockers, verapamil and diltiazem, is much more limited due to the 
potential for severe cardiac depression and must be used with great caution. In the long-
term management of ischemic heart disease, ǃ-adrenoceptor antagonists, with their 
antianginal effects, may also be combined with vasculoprotective drugs such as anti-platelet 
agents (aspirin, clopidogrel), angiotensin-converting enzyme inhibitors, and HMG-CoA 
reductase inhibitors to reduce the risk of ischemic vascular events.  
2.3 Calcium entry blockers (CEBs) 
The mode of action of most conventional antianginal agents involves hemodynamic 
changes, such as a reduction in systemic vascular resistance or coronary vasodilatation or 
negative inotropism, which improve the imbalance in myocardial oxygen supply and 
demand. CEBs bind to and inhibit L-type calcium channels, reducing calcium influx into 
cells. Intracellular calcium deprivation relaxes smooth muscle cells, causing vasodilation in 
the peripheral and coronary beds and increased coronary blood flow. The less selective, 
nondihydropyridine (DHP) CEBs, verapamil and diltiazem, also slow sinoatrial (SA) and 
atrioventricular (AV) nodal conductions to lower heart rate and depress contractility under 
physiological conditions. All the CEBs are effective coronary vasodilators. DHPs lower 
blood pressure and myocardial wall tension to reduce myocardial oxygen consumption. A 
rise in coronary blood flow further contributes to correct myocardial oxygen imbalance. 
These drugs lower the frequency of angina, reduce the need for nitrates, extend treadmill 
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walking time, and improve ischemic ST-segment changes on exercise testing and 
electrocardiographic monitoring. Amlodipine, in particular, may have some independent 
action in relieving diastolic dysfunction other than a reduction in blood pressure. CEBs find 
clinical use in patients who cannot tolerate ǃ-blockers, when they are ineffective, and in 
combination for additive anti-ischemic effects. Although they are effective antianginal 
agents, they do not modify the natural progression of the disease. The large International 
Verapamil-Trandolapril Study (INVEST) trial reported a reduction in number of patients 
with angina from about 65%–25% using verapamil as compared with atenolol, with no 
difference in mortality over a 2-year period (Pepine et al., 2003). When DHPs are used in 
combination with ǃ-blockers, reflex tachycardia from the CCBs is blunted. Long-acting 
DHPs are preferred. If clinically needed, verapamil or diltiazem may be used with caution 
to lower heart rate or slow AV conduction further when ventricular function is preserved. In 
patients with stable angina and hypertension, ǃ-blockers in combination with amlodipine 
and long-acting nifedipine, nicardipine, isradipine, or felodipine offer an advantage. Of all 
agents available, the greatest clinical experience has been with amlodipine and felodipine. 
Short-acting nifedipine has been linked to an increase in myocardial infarction (MI) and 
should be avoided in unstable angina or ACS. The A Coronary Disease Trial Investigating 
Outcome with Nifedipine GITS (ACTION) study showed that long-acting nifedipine 
(gastrointestinal therapeutic system) safely relieved angina and prolonged event-free 
survival in patients with stable angina and hypertension (Poole-Wilson et al., 2004; Sierra 
and Coca, 2008). Verapamil acts chiefly through a negative inotropic action, with less 
associated reflex tachycardia; diltiazem has greater vasodilatory actions than verapamil. 
Both verapamil and diltiazem are contraindicated in patients with uncompensated heart 
failure (HF) because of their negative inotropic effects; amlodipine and felodipine appear 
safe when left ventricle (LV) dysfunction is compensated. Use of non-DPHs after complex 
MIs should be avoided because of the possibility of HF as well (Packer et al., 1996; Goldstein 
et al., 1991). DHPs, particularly nifedipine, are effective in managing Prinzmetal’s variant 
angina along with long-acting nitrates. Although CCBs are effective anti-ischemic agents, in 
patients with UA/ STEMI, they do not improve mortality. Diltiazem and verapamil are 
contraindicated in patients with STEMI accompanied by systolic LV dysfunction and HF. 
Immediate release forms of DHPs-CCBs are contraindicated in STEMI because reflex 
tachycardia increases myocardial oxygen demand and hypotension potentially lowers 
coronary perfusion pressure. Also, they should not be used in UA/STEMI without a ǃ-
blocker. Common side effects of headache, dizziness, flushing, and edema are due to 
vasodilation. Interaction with other negative chronotropic or inotropic agents to produce 
bradycardia, heart block, or HF has been reported. CCBs may also suppress lower 
esophageal sphincter contraction and worsen symptoms of gastroesophageal reflux disease. 
CEBs inhibit the CYPA4 enzyme in the liver and, therefore, may raise levels of statins and 
many other drugs, which may be overlooked (Kones, 2010). Cimetidine and grapefruit juice 
may raise the effective level of CEBs. Since magnesium is a calcium antagonist, magnesium 
supplements may enhance the actions of CEBs, particularly nifedipine. Chronotherapy with 
CCBs has been designed to achieve the highest plasma concentration during the most 
vulnerable time period while maintaining an adequate therapeutic dose throughout the 
remainder of the 24 hour period and has been marketed in the US since 1996. A variety of 
CCBs delivery formulations (e.g., with controlled-onset and/or extended release) have been 
approved by the FDA, and may be beneficially prescribed to lower blood pressure, heart 
rate and rate-pressure product between 6:00 A.M. and noon depending on the time of 
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administration. Another study demonstrated an improvement in the duration of exercise 
with evening doses of this diltiazem preparation versus morning dosing. 
3. Novel antianginal 
New drugs based on novel mechanisms of action have emerged (Chaitman, 2005). 
3.1 Ranolazine  
Ranolazine (approved by the US Food and Drug Administration) is a unique anti‐ischaemic 
drug that does not significantly affect haemodynamic parameters (Siddiqui et al., 2006). It 
was originally believed to modify the use of substrate by the ischaemic myocardium from 
lipids to glucose, thereby increasing metabolic efficiency. However, recent studies suggest 
that it inhibits the late sodium current (INA) and the accumulation of intracellular sodium 
and congruent cellular calcium overload via the sodium/calcium exchanger. As opposed to 
treatment with calcium channel antagonists and ǃ‐blockers, the ranolazine‐induced 
improvement in diastolic function occurs without a decrease in systolic function. Clinical 
studies of the anti‐ischaemic effect of ranolazine monotherapy in patients with stable angina 
showed a significant increase in exercise duration and an improved 1 mm ST-segment 
depression compared with atenolol. As an adjunct to standard doses of anti‐ischaemia drugs 
(atenolol, amlodipine, diltiazem), ranolazine had an additional antianginal and 
anti‐ischaemic effect, without causing significant hemodynamic changes. The ERICA study 
addressed the incremental benefit of adding ranolazine to maximal amlodipine regimen. 
Ranolazine significantly reduced the frequency of angina and GTN consumption compared 
with placebo. It also has another potentially favorable effect-namely, a dose‐related 
reduction in haemoglobin (HbA1c %) concentrations in diabetic patients. More comparative 
trials of ranolazine with other antianginal agents and studies of its effects on long‐term 
morbidity and mortality are needed. So far, results indicate that ranolazine may serve as a 
useful alternative or adjunct to conventional antianginal treatment. Adverse effects include 
constipation, nausea, and dizziness. Postural hypotension due to ǂ‐adrenergic receptor 
blocking has also been reported. Increases in QT- interval were observed but not associated 
torsade de points. 
3.2 Trimetazidine  
Trimetazidine (1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride) selectively inhibits 
the mitochondrial long chain 3-ketoacyl coenzyme A thiolase. It is widely used for the 
prophylactic treatment of episodes of angina pectoris at recommended daily doses ranging 
from 40–60 mg. Trimetazidine is a pure metabolic agent that induces the myocardium to 
shift from free fatty acids to predominantly glucose utilisation in order to increase adenosine 
triphosphate (ATP) generation per unit oxygen consumption. The antianginal properties of 
trimetazidine were previously shown in acute and chronic experimental conditions in which 
the cardioprotective effects were related to the positive effects on energy metabolism, 
hydroionic balance, coronary microcirculation, and oxidative stress. Efficacy studies 
reported that trimetazidine reduced ischemia during exercise stress tests, but there was no 
improvement in outcome. In a Cochrane meta‐analysis of 23 studies including 1378 patients, 
trimetazidine was associated with a significant reduction in weekly angina episodes and 
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improved exercise time to 1 mm ST-segment depression compared to placebo (Ciapponi et 
al., 2005). In patients with stable angina who experienced concomitant erectile dysfunction, 
trimetazidine plus sildenafil was both safe and more effective in controlling episodes of 
ischaemia during sexual activity than nitrates alone. These data indicate that trimetazidine is 
safe and effective for the treatment of symptoms of stable angina, either as monotherapy or 
adjunctive treatment. The Di Napoli study (2005) indicated that trimetazidine added to 
usual treatment improved the functional status of patients with ischaemic dilated 
cardiomyopathy, as shown by their distribution in the NYHA class after 18 months of 
treatment. Compared with control patients maintained with their usual treatment, 
trimetazidine treated patients’ functional improvement was associated with a significant 
increase in left ventricle ejection fraction and a significant effect on ventricular remodelling. 
These effects were significant starting from 12 months and were maintained after 18 months 
of treatment. Bonello et al., (2007) demonstrates that pretreatment with a 60 mg acute oral 
loading dose of trimetazidine before elective percutaneous coronary intervention limits 
myocardial damage, as shown by a lower total amount of troponin (cTnI) release after 
coronary angioplasty.  
3.3 Ivabradine  
Few agents were developed for If inhibition in the past; the first of which is Alinidine, a 
clonidine derivative, that was soon abandoned due to its relative inotropic action (Ogiwara 
et al., 1988). Later, zetabradine, a benzazepinone derivative also went out of contention due 
to unacceptable ocular side effects and QTc prolongation (Frishman et al., 1995; Frishman et 
al., 2003). Ivabradine, a unique specific If current inhibitor, was first described by Thollon et 
al., more than two decades ago (Thollon et al., 1994). The If current inhibitor ivabradine was 
approved for the treatment of stable angina pectoris by the European Medicines Agency 
(EMEA) in 2005. Ivabradine is an inhibitor of the selective cardiac pacemaker 
hyperpolarized-activated If current, one of the most important pacemaker currents in the 
sinoatrial node (DiFrancesco & Camm 2004; Zaza & Rocchetti 2005). Ivabradine has no 
negative inotropic or hypotensive effects and is therefore a pure heart rate-lowering agent, 
in contrast to beta blockers. The pure heart rate-reducing effect of ivabradine offers the 
advantage of not disturbing hemodynamic parameters or left ventricular systolic and 
diastolic functions. Moreover, the increase in the duration of diastole is greater with 
ivabradine than with atenolol for a given heart rate (Colin et al. 2003), a beneficial 
phenomenon considering that most of the coronary perfusion occurs during diastole. 
Double‐blind trials showed that ivabradine treatment increased exercise time to 1 mm ST-
segment depression and limited angina compared to placebo, and had similar clinical effects 
to atenolol or amlodipine—namely, a two‐third reduction in the number of anginal episodes 
and an increase in total exercise duration. Ivabradine offers clear therapeutic benefit for a 
whole range of patients with stable angina, including those with contraindication or 
intolerance to ǃ‐blockers; however, its effect on survival remains to be explored. Visual 
symptoms and sinus bradycardia are the main adverse reactions observed with the use of 
ivabradine. The visual symptoms are mainly phosphenes, which are episodes of enhanced 
brightness in limited areas of the visual field frequently triggered by abrupt changes in light 
intensity. They include photopsia, stroboscopic effect, and non-typical blurred vision, 
among others. However, the symptoms are generally transient, mild, and do not affect daily 
living activities. The visual symptoms are probably caused by the interaction of ivabradine 
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with retinal hyperpolarization-activated h channels, responsible for responses to bright light 
stimuli, which are similar to the f ion channel located in the sinoatrial node (Demontis et al. 
2002; Savelieva & Camm 2006). Sinus bradycardia has been reported by 4.6% of patients 
treated with ivabradine 7.5 mg twice daily (Tardif et al. 2005; Ruzyllo et al. 2007). Severe 
bradycardia (defined as a heart rate less than 40 beat/minute) has been shown to occur in 
0.1% of patients. The QTc-interval was not increased in ivabradine recipients compared with 
atenolol. 
3.4 Fasudil hydrochloride 
[1-(5-isoquinolinesulfonyl)-homopiperazine] is a potent Rho-kinase (an intracellular 
signalling molecule involved in the vascular smooth muscle contractile response) inhibitor 
and vasodilator, used for the treatment of cerebral vasospasm, which is often due to 
subarachnoid hemorrhage, as well as to improve the cognitive decline seen in stroke 
victims. It has been found to be effective for the treatment of pulmonary hypertension. It 
was demonstrated in February 2009 that Fasudil could also be used to enhance memory and 
improve the prognosis of Alzheimer's patients. In patients with stable angina, fasudil 
treatment led to a significantly greater time to >1 mm ST-segment depression, but showed 
no difference from placebo in decreasing the time to angina, frequency of angina, or GTN 
use. In phase 2 dose-finding trials conducted in Japanese patients with stable effort angina, 
fasudil monotherapy at doses ranging from 5 mg three times daily to 40 mg three times 
daily increased maximum exercise time and time to the onset of ≥ 1 mm ST-segment 
depression compared with baseline. Fasudil was well tolerated, with minimal effects on 
blood pressure or heart rate at rest or during exercise (Shimokawa et al., 2002). 
Intracoronary fasudil ameliorate myocardial ischemia induced by intracoronary injection of 
acetylcholine in patients with cardiac syndrome X or microvascular angina (angina with 
normal coronary arteriogram) (Mohri et al., 2003). 
3.5 Molsidomine  
Molsidomine is a nitric oxide donating vasodilator. When compared with placebo, it 
reduced the incidence of anginal attacks and use of sublingual nitrates, and increased 
exercise capacity, in patients with stable angina. Higher doses provided better protection 
from angina, although hypotension was a side effect. These new drugs are not yet in routine 
clinical use; however, they may serve as useful alternatives or adjuncts to conventional 
antianginal treatment. Further studies and longer follow‐up will determine their place in 
preventing death or myocardial infarction. 
3.6 Potassium channel openers (KCOs)  
Potassium-ATP (KATP) channels serve as endogenous homeostatic transducers balancing 
cellular resources in response to altered demand. In the heart, KATP channels protect against 
the metabolic insult of ischemia, and contribute as molecular mediators in the adaptive 
response to distress. Moreover, KATP channels regulate vascular tone, and thereby the 
delivery of metabolic resources to match demand.The possible smooth muscle relaxation 
mechanisms associated with KATP channels in the coronary artery are; in the endothelial cells 
the KATP channels are activated by adenosine and ǂ2-adrenoceptor stimulation and 
contribute to generation of nitric oxide, in the sympathetic neurons opening of presynaptic 
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KATP channels attenuates noradrenaline release. KCOs would enhance these exo-smooth 
muscle actions of the KATP channels and dilate the coronary artery. KCOs are chemically 
diverse, and belong to a number of structural classes. These include: 
-  Benzopyrans (levcromakalim, bimakalim) 
-  Benzothiadiazines (diazoxide) 
- Cyanoguanidines (pinacidil) 
-  Cyclobutenediones (WAY-151616) 
-  Nicotinamides (nicorandil)  
- Pyrimidines (minoxidil) 
-  Tertiary carbonoles (ZD-6169) 
-  Thioformamides (aprikalim) 
- Dihydropyridine-like structures (ZM-244085) 
3.7 Nicorandil  
Nicorandil exerts dual actions: it increases the opening of ATP‐gated K+ channels, thereby 
relaxing smooth muscle and contributing to coronary vasodilatation; and it has a 
nitrate‐donating moiety. As well as anti‐ischaemic effects, nicorandil may have a 
cardioprotective action. Nicorandil may mimic the natural process of ischemic 
preconditioning, which involves ATP‐dependent potassium channels. Several small 
randomized trials of patients with stable angina have shown that nicorandil prolongs the 
time to onset of ST-segment depression and exercise duration during stress testing and 
improves myocardial perfusion at rest and with exercise. In patients, nicorandil has been 
shown to be useful in the management of both stable and unstable angina with minimum 
adverse effects (Simpson et al., 2004). Nicorandil attenuated rest and effort angina, 
prolonged the duration of exercise and the time to onset of angina or ischemic ST-T changes 
(Markham et al., 2000). Long-term use of nicorandil was associated with reduction in 
cardiovascular events and the combined endpoints of death, myocardial infarction and 
hospitalization due to chest pain in patients with stable angina [The IONA Study Group, 
2001]. Nicorandil is an effective anti-anginal agent at a dose of 10 to 40 mg twice a day, 
controlling stable chronic angina in 70 to 80 percent of patients (Simpson et al., 2004). The 
response to nicorandil is maintained for 12 hours, with an efficacy that compares favorably 
with that of nitrates, ǃ-adrenoceptor and CEBs. In patients with unstable angina, nicorandil, 
when added to aggressive anti-anginal treatment, reduces transient myocardial ischemia, 
and arrhythmias when compared to placebo (Patel et al., 1999). In vasospastic angina, 
nicorandil, with potent vasospasmolytic activity, relieves both ergonovine-evoked and 
spontaneous coronary spasm, attenuates episodes of variant angina, suppresses ST-segment 
changes and improves perfusion defects. In MI, nicorandil improves ischemia-induced 
regional wall motion abnormalities, and perfusion in infarct-related areas. In the IONA trial 
of 5126 patients, the administration of nicorandil in addition to standard treatments reduced 
the primary end point (coronary death, MI, or hospitalisation for angina) by 17% after a 
mean follow‐up of 1.6 years. There was also a significant reduction in the incidence of ACS 
and all cardiovascular events (IONA Study Group et al., 2002). In patients undergoing 
angioplasty, nicorandil preconditions the heart, improves coronary hemodynamics, dilates 
stenotic and non-stenotic segments, and ameliorates the “no-reflow” phenomenon (Yasuda 
et al., 2001). Intravenous nicorandil, in conjunction with coronary angioplasty, preserves 
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microvascular integrity and myocardial viability in patients with acute myocardial 
infarction (Simpson et al., 2004). Nicorandil also reduces preload and afterload, enhances 
cardiac endothelial nitric oxide synthase expression and has antiplatelet, fibrinolytic and 
antioxidant properties (Simpson et al., 2004). Unlike GTN, no development of tolerance to 
the antianginal effect of nicorandil has been reported (Simpson et al., 2004). Main side-
effects include headache, gastrointestinal disturbances and dizziness, mucosal ulceration, 
including stomatitis and mouth and anal ulcerations. No evidence of proarrhythmia, 
conduction disturbance, exacerbation of myocardial ischemia, infarction, abrupt withdrawal 
syndrome, symptomatic decrease in blood pressure or change in heart rate has been 
observed (Simpson et al., 2004;The Lona Study Group, 2001). Also, no adverse interaction 
has been reported in patients on oral anticoagulants or hypoglycemic agents. The 
pharmacokinetics of nicorandil is unaltered in the elderly or patients with renal or hepatic 
insufficiency (Simpson et al., 2004). Other KCOs like Levcromakalim, aprikalim and 
KRN4884 relax conduit arteries (internal mammary and gastroepiploic arteries) used as 
coronary artery bypass grafts and could be useful in preventing spasm of bypass grafts in 
patients undergoing surgery for atherosclerotic heart disease. 
3.8 Antiplatelets 
Antiplatelet agents are the cornerstone of treatment for patients with ACS undergoing 
percutaneous coronary intervention (PCI).  
3.8.1 Acetylsalicylic acid (Aspirin) 
Platelet activation and aggregation after vulnerable plaque rupture with resultant 
thromboses of varying degrees are key components in the pathophysiology of ACS. 
Acetylsalicylic acid (ASA), causes irreversible acetylation of serine 529 of cyclooxygenase 
(COX-1) in platelets and the endothelium, thereby preventing thromboxane A2 (TXA2) 
production and resultant platelet aggregation. Studies have shown that ASA reduces the 
risk of angina, death, or MI by approximately 30% in patients with coronary artery disease 
(Collaborative overview of randomised trials of antiplatelet therapy-I, 1994; Antithrombotic 
Trialists’ Collaboration, 2002). Although ASA is beneficial for preventing and treating vascular 
disease, ASA does not prevent all thrombotic events from recurring. Patients who have an 
ischemic event and are taking aspirin actually may have worse outcomes than do patients who 
are not taking aspirin (Alexander et al., 1999). This observation that led to the concept of 
“aspirin resistance (Bhatt and Topol, 2003; Patrono, 2003), a term that has been used when 
ASA is ineffective for protecting patients from thrombotic complications, for prolonging 
bleeding times, or for decreasing TXA2 production. Potential causes of aspirin resistance 
include inadequate dosing, drug interactions, genetic polymorphisms of COX-1 and other 
genes involved in TXA2 production, and upregulation of non-platelet sources of TXA2 
production (Hankey and Eikelboom, 2006). Unfortunately, the optimal treatment for aspirin 
resistance, if any, is unknown. The Altering aspirin therapy after a laboratory finding of 
aspirin resistance could be both safe and helpful (Michelson et al., 2005). Aspirin has been 
shown to be beneficial in the primary prevention, secondary prevention, and treatment of ACS 
because of the important role of platelets in thrombus formation. One study suggested that 
prior aspirin use by those who develop an ACS may actually predispose to worse outcomes 
than those not previously taking aspirin (i.e. aspirin paradox) (Santopinto et al., 2001).  
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From the Thrombolysis In Myocardial Infarction (TIMI) trials database of 66,443 patients, 
Rich et al., (2010) demonstrated that prior aspirin use is associated with a high-risk cohort of 
patients but not associated with increased mortality after an ACS, emphasizing that it is 
likely more a marker as opposed to a pathophysiologic factor related to an increased risk. 
Prior aspirin use was associated with an increase in the risk of recurrent myocardial 
infarction and the composite end point of death/recurrent myocardial infraction/ischemia 
requiring urgent revascularization/recent ischemia requiring hospitalization/stroke. This 
may be attributable to confounders that cannot be corrected for, aspirin resistance, or both.  
3.8.2 Thienopyridines 
Thienopyridines, such as ticlopidine, clopidogrel, and the newer agent prasugrel, block 
P2Y12 receptor signaling to prevent production of adenyl cyclase, thereby inhibiting platelet 
activation through adenosine diphosphate (ADP). They also limit ADP-mediated conversion 
of glycoprotein receptor (GPIIb/IIIa) to its active form. Their mechanism of action is 
independent of and complementary to that of aspirin, and the combination of agents is 
superior to aspirin alone. Because thienopyridines take longer than aspirin to cause 
irreversible antiplatelet effects, a loading dose usually is administered. The thienopyridines 
are prodrugs that must be metabolized in vivo into active form. Both prasugrel and 
clopidogrel require CYP450 metabolism for the generation of active metabolites, but the 
pathways leading to conversion to the active metabolites differ between the prodrugs. 
3.8.2.1 Ticlopidine 
A 1st-generation thienopyridine, in combination with ASA, is associated with reducing rates 
of vascular death and MI by 46% in NSTEMI patients (Balsano et al., 1990). It has also been 
shown to be superior to oral anticoagulants in preventing thrombotic complications after 
coronary stent placement (Urban et al., 1998). However, it is used less frequently than the 
newer thienopyridines in current clinical practice because of its potential for side effects 
primarily rash, nausea, neutropenia, and thrombocytopenia (Love et al., 1998). 
3.8.2.2 Clopidogrel  
Second generation thienopyridine, is the most widely studied and used ADP-receptor-
blocking agent. Initial data regarding clopidogrel are derived from the Clopidogrel versus 
Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) study [1996] which reported a 9% 
relative risk reduction in adverse cardiovascular events (vascular death, MI, or ischemic 
stroke) without a significant increase in bleeding. Also this study showed that the risk of the 
primary composite endpoint (cardiovascular death, MI, or stroke) was reduced 20% with the 
use of clopidogrel compared to aspirin. Clopidogrel has demonstrated considerable success 
in reducing thrombotic complications of ACS and/or PCI compared to aspirin alone and is 
standard of care for the management of patients with ACS and when added in patients 
undergoing PCI. In elderly STEMI patients who receive thrombolytics, a loading dose of 
clopidogrel is not recommended due to increased risk of intracerebral hemorrhage. Loading 
dose of clopidogrel is recommended in elderly STEMI patients only if primary PCI is 
performed. In UA/NSTEMI patients with a history of gastrointestinal bleeding, ASA and 
clopidogrel should be given with other agents, such as proton pump inhibitors (PPIs) that 
minimize the risk of recurrent gastrointestinal bleeding. Clopidogrel therapy must also be 
stopped 4 to 7 days before elective coronary artery bypass grafting (CABG), to prevent 
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excessive intraoperative and post-operative bleeding (Mehta et al., 2006; Chu et al., 2004). As 
a result, clinicians might have to delay giving clopidogrel to patients who are undergoing 
early coronary angiography (within 48 hr of hospital admission) until it is clear that these 
patients will not undergo a coronary artery bypass graft surgery (CABG) procedure within 
the next several days. However, there is growing evidence to support broad variability 
among individual patient responses to clopidogrel. This clopidogrel resistance is associated 
with a higher risk of recurrent ischemic complications (Serebruany et al., 2005). The 
mechanisms underlying the variability of response to clopidogrel may be related to poor 
patient compliance, differences in clopidogrel dosing, gastric absorption problems, and 
varying availability and clearance of the active metabolite (O'queli et al., 2007). Genetic 
factors including polymorphisms of hepatic CYP3A—have received special attention (Frere 
et al., 2008). There have been reports of concerns that proton pump inhibitors (PPIs) may 
interfere with clopidogrel’s ability to inhibit platelet aggregation, thereby increasing the risk 
of rehospitalization or death in association with ACS (Li et al., 2004; Juurlink et al., 2009; Ho 
et al., 2009). Combined use of clopidogrel and PPIs was associated with an increased risk of 
death from or rehospitalization for ACS when compared with use of clopidogrel alone (Ho 
et al., 2009). 
3.8.2.3 Prasugrel  
It is an orally administered P2Y12 receptor antagonist that is more potent, more rapid in 
onset, and more consistent in its inhibition of platelet aggregation than clopidogrel. In 
clinical studies, prasugrel has consistently demonstrated greater and more rapid platelet 
inhibition than clopidogrel in healthy subjects, patients with stable coronary artery disease 
and acute coronary syndrome, and those undergoing percutaneous coronary intervention. 
In addition, subjects who are poor responders to clopidogrel respond adequately to 
prasugrel (Brandt et al., 2007; Weerakkody et al., 2007a; 2007b). In the Assess Improvement 
in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Throm-bolysis in 
Myocardial Infarction (TRITON-TIMI 38) trial, prasugrel significantly reduced the 
composite endpoint of cardiovascular death, nonfatal MI, or non-fatal stroke by 19%, when 
compared with clopidogrel (Wiviott et al., 2007). Prasugrel also reduced MI by 24%, the 
need for urgent revascularization by 34%, and stent thrombosis by 52% (Wiviott et al., 2008). 
However, the beneficial effect also was associated with a 0.5% absolute increase in non-
CABG-related TIMI major bleeding and life-threatening bleeding and a 0.3% absolute 
increase in fatal bleeding (Wiviott et al., 2007). TRITON-TIMI 38 trial showed that patients 
with a history of transient ischemic attack or stroke, those who were 75 years or older, and 
those who weighed less than 60 kg were especially at risk of bleeding mainly during the 
maintenance phase (Wiviott et al., 2008; Murphy et al., 2008). 
3.8.3 Nonthienopyridine antiplatelet agents 
Cangrelor and Ticagrelor are direct and reversible inhibitors of the platelet P2Y12 receptor. 
SCH 530348 is an oral protease-activated receptor-1 antagonist. 
3.8.4 Glycoprotein IIb/IIIa inhibitors 
The final common pathway of platelet activation and aggregation involves a conformational 
change of the GPIIb/IIIa receptors from a resting state to an active state. The activated 
www.intechopen.com
 
Coronary Artery Diseases 
 
166 
GPIIb/IIIa receptors undergo bivalent binding with soluble ligands, with fibrinogen, and, 
under high shear conditions, with von Willebrand factor, which leads to fibrinogen-
mediated cross-linking of platelets; a key event in thrombus formation and thrombosis. 
GPIIb/IIIa inhibitors are potent inhibitors of platelet aggregation by all types of stimuli (for 
example, ADP, serotonin, collagen, and thrombin). Currently three types of GPIIb/IIIa 
inhibitors are used clinically: abciximab, tirofiban, and eptifibatide.  
3.8.4.1 Abciximab  
It is a recombinant human-murine chimeric Fab-fragment with a half-life of 10 minutes. 
Abciximab was initially studied in percutaneous trans-luminal coronary angioplasty (PTCA) 
trials, in the prestent era of the early 1990s. However, the advent of GPIIb/IIIa inhibitors 
revolutionized the use of catheter-based therapies in the treatment of peripheral artery 
disease, cerebrovascular atherosclerotic disease, and various forms of coronary artery 
disease, as well as stable angina, UA, NSTEMI, and STEMI. Results from the Evaluation of 
c7E3 for the Prevention of Ischemic Complications (EPIC) trial showed that in relatively 
high-risk patients (those with UA, evolving MI, or complex angiographic lesion 
morphology) who were given abciximab, there was a 35% reduction in the primary 
composite end-point (death, MI, or recurrent ischemia) compared with patients who 
received a placebo (EPIC investigation, 1994). The c7E3 Fab Antiplatelet Therapy in 
Unstable Refractory Angina (CAPTURE) trial [1997] showed a 30% relative reduction, 
within 30 days after PTCA, in the primary endpoint of death (any cause), myocardial 
infarction, or recurrent ischemia requiring urgent revascularization. Furthermore, abciximab 
reduced the rate of myocardial infarction before, during, and after PTCA, even in patients 
given nitrates and heparin. Also revealed that abciximab facilitated thrombus resolution and 
prevented recurrent ischemia, as measured by continuous electrocardiographic monitoring. 
The Global Use of Strategies to Open Occluded Coronary Arteries IV–Acute Coronary 
Syndrome (GUSTO IV-ACS) trial studied 7,800 UA/NSTEMI patients who were not 
scheduled to undergo early revascularization. The results of the study showed that 
abciximab administration provided no benefit, even in a subgroup of patients who had 
elevated troponin levels (Simoons et al., 2001). 
3.8.4.2 Tirofiban hydrochloride  
It is a low molecular weight nonpeptide derivative of tyrosine with a half-life of 1.3 hours. In 
the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study (1998), 
3,232 patients with UA were randomlyassigned to receive either heparin or tirofiban for 48 
hours. Results showed a 32% reduction in the rate of death, MI, or refractory ischemia at 48 
hours (3.8% with tirofiban vs 5.6% with heparin), but there was no significant difference in 
the composite endpoint at 30 days (15.9% in the tirofiban group vs 17% in the heparin 
group). In the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients 
Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial (1998) 1,915 patients with UA 
and non-Q-wave MI were randomly assigned to receive heparin, tirofiban, or both. Patients 
also received ASA in the absence of any contraindications. The tirofiban only arm was 
stopped prematurely because of excess death at 7 days (4.6% vs 1.1% in the heparin-only 
arm). The greatest benefit was seen in the group receiving both heparin and tirofiban, for 
whom the frequency of the composite endpoint (7-day death, MI, or refractory ischemia) 
was reduced (17.9% vs 12.9% in the heparin-only arm). The observed benefit was sustained 
at 30 days (18.5% vs 22%) and at 6 months (27.7% vs 32%).  
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3.8.4.3 Eptifibatide  
It is a cyclic heptapeptide that selectively inhibits the arginin-glycin-aspartate (RGD) motifs 
sequence of the GPIIb/IIIa receptors and has a half-life of 150 minutes. The Platelet 
Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy 
(PURSUIT) trial (1998) data showed that the administration of eptifibatide resulted in a 10% 
reduction in the relative risk of death and MI at 30 days in patients who had NSTEMI. 
Boersma and colleagues (2002) clarified the importance of GPIIb/IIIa inhibitors in the 
management of moderate to high-risk UA/NSTEMI patients. Boersma’s meta-analysis 
pooled 31,402 patients from six GPIIb/IIIa trials for ACS. Results showed a 10.8% event rate 
in the GPIIb/IIIa inhibitor group (n=18,297), versus an 11.8% event rate in the placebo 
group (n=13,105), and a 9% reduction in the odds ratio of death or MI. The benefit was 
largest in a subset of patients who had evidence of myocardial necrosis, as suggested by 
elevated troponin levels. The magnitude of the treatment effect also was found to be greater 
in patients who underwent a PCI procedure within 5 days. The Early GPIIb/IIIa Inhibition 
in Non-ST-Segment-Elevation Acute Coronary Syndrome (EARLY ACS) trial (Giugliano et 
al., 2009) studied 9,494 high-risk NSTEMI patients undergoing an invasive procedure at 
study centers in 29 countries were randomly assigned to receive either eptifibatide ≥12 
hours before angiography (the early eptifibatide group) or a matching placebo infusion with 
provisional use of eptifibatide after angiography (the delayed-eptifibatide group). Results 
showed no statistical difference in the primary efficacy endpoint of a composite of death, 
MI, or recurrent ischemia requiring urgent revascularization, or in the occurrence of a 
thrombotic complication during PCI (9.3% in the early-eptifibatide group vs 10% in the 
delayed-eptifibatide group). However, early use of eptifibatide was associated with an 
increased risk of nonfatal bleeding and the need for transfusion (Giugliano et al., 2009). 
3.9 Anticoagulants 
Anticoagulants are effective for reducing the occurrence of major ischemic events in patients 
with ACS. The principal adverse effect associated with their use is bleeding. Bleeding 
during anticoagulant therapy is independently associated with an increased risk of MI and 
death, which further offsets the clinical benefit (Eikelboom et al., 2006; Rao et al., 2004). In 
the treatment of non-ST elevation (NSTE) ACS, enoxaparin, a low-molecular-weight heparin 
(LMWH), reduces the odds of death or non-fatal MI by 16% compared with unfractionated 
heparin (UFH) (odds ratio [OR]: 0.84; 95% C.I: 0.76-0.92) but does not reduce death and 
increases the odds of major bleeding by 25% (OR: 1.25; 95% CI: 1.04-1.50) (Murphy et al., 
2007). In the treatment of STEMI, enoxaparin compared with UFH reduces the odds of death 
or non-fatal MI by 22%, but increases the risk of bleeding by 45% and is not associated with 
a mortality benefit. Another LMWH, reviparin, reduces both reinfarction and mortality 
among patients with acute STEMI compared with standard treatment, but increases the risk 
of life-threatening bleeding (Yusuf et al., 2005). 
3.9.1 Unfractionated heparin (UFH) 
Unfractionated heparin is a glycosaminoglycan comprising multiple different polysaccharide 
chain lengths of varying molecular weights. It exerts its anticoagulative effect by activating 
and accelerating the proteolytic activity of plasma cofactor antithrombin (AT). Heparin 
binds to the lysine site on AT, producing a conformational change at the arginine-reactive 
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site that converts AT from a slow, progressive thrombin (factor IIa) inhibitor to a rapid 
inhibitor of thrombin and factor Xa thereby preventing thrombus propagation. Only one 
third of any given dose of heparin actually binds to AT and exerts its anticoagulative effect. 
Heparin also binds to a number of different circulating plasma proteins (acute phase 
reactants), blood cells, and endothelial cells, which contributes to its differing 
anticoagulative effects in different patients. Therefore, close and frequent monitoring of the 
activated partial thromboplastin time is necessary to ensure that a safe therapeutic range  
is maintained. In a double-blind, randomized, placebo-controlled trial involving 479 
UA/NSTEMI patients, the incidence of MI was reduced from 11.9% in the placebo group to 
3.3% in the ASA group, 0.8% in the heparin group, and 1.6% in the heparin plus ASA group 
(Theroux et al., 1988). Similarly, the incidence of refractory angina was reduced from 22.9% 
in the placebo group to 16.5% in the ASA group, 8.5% in the heparin group, and 10.7% in the 
heparin plus ASA group. The combination of heparin plus ASA was found to be no more beneficial 
than heparin alone. Meta-analysis using data from 6 randomized trials that included 1,353 
patients found that patients who received a combination of UFH and ASA had a 33% risk 
reduction in cardiovascular death and MI (95% C.I, 2%–56%) than did patients who received 
a placebo (Oler et al., 1996). The ACC/AHA Guidelines state that patients with NSTEMI should 
receive heparin, unless contraindicated. Most trials of UFH involving UA/NSTEMI patients 
recommend heparin therapy for 2 to 5 days. 
3.9.2 Low-molecular-weight heparin 
Low-molecular weight heparin is derived from heparin by chemical or enzymatic 
depolymerization, which yields fragments approximately one third the size of heparin. Most 
of the fragments contain fewer than 18 saccharide units and catalyze the inactivation of 
factor Xa more than of factor IIa (UFH inhibits factors Xa and IIa equally) (Weitz, 1997). 
Compared with UFH, LMWH has lower plasma-protein binding and therefore, a more 
predictable anticoagulative effect, has a greater bioavailability, is conveniently administered 
in subcutaneous doses (once/day or twice/day), and requires less frequent laboratory 
monitoring. Because LMWH is cleared by the kidneys, dosing should be decreased to half in 
patients with creatinine clearances of <30 ml/min and avoided altogether in patients with 
severe renal insufficiency. LMWHs; ardeparin, dalteparin, enoxaparin, nadroparin, 
reviparin, and tinzaparin are now considered the mainstay of antithrombotic agents for the 
prophylaxis and treatment of venous thrombo-embolism (VTE). Dalteparin, enoxaparin, and 
tinzaparin are all approved by the FDA and currently available in the United States. The 
FDA-approved indications vary among the different LMWHs. Dalteparin and enoxaparin 
are indicated for VTE prophylaxis and ACS treatment, while enoxaparin and tinzaparin are 
indicated for treatment of VTE. As enoxaparin has been available since the early 1980s, it is 
the LMWH most widely studied, as reflected by its extended list of FDA-approved 
indications. Fast Revascularization during Instability in Coronary Artery Disease (FRISC) 
trial found that dalteparin (120 IU/kg with a maximal dose of 10,000 IU, twice daily) was 
associated with a 63% relative risk reduction in death or MI (1.8% in the treatment group vs 
4.8% in the placebo group) in the first six days (Swahn and Wallentin, 1997). At 40 days, 
differences in the incidence of MI and death in patients receiving dalteparin persisted, 
although a sub-group analysis revealed that dalteparin’s effect was mostly confined to 
patients who were nonsmokers. In the Efficacy and Safety of Subcutaneous Enoxaparin in 
Non-Q-wave Coronary Events (ESSENCE) trial found that the risk of death, MI, or recurrent 
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angina in patients with UA/NSTEMA was significantly lower in the enoxaparin (1 mg/kg 
twice daily) patients than in the UFH patients (16.6% vs 19.8%). Even at 30 days, the benefit 
remained (19.8% vs 23%), but at the cost of increased minor bleeding (Cohen et al., 1997). 
There was no significant change in the incidence of major bleeding (6.5% vs 7%). The 
Thrombolysis In Myocardial Infarction 11B (TIMI 11B) trial found that enoxaparin may be 
more effective than UFH for reducing death and serious cardiac ischemic events during the 
acute management of UA/NSTEMI patients, without causing a significant increase in the 
rate of major bleeding (Antman et al., 1999). A meta-analysis of the approximately 22,000 
UA/NSTEMI patients enrolled in six randomized trials comparing enoxaparin and UFH 
showed a relative risk reduction of 9% in the combined endpoint of death or MI at 30 days 
for patients receiving enoxaparin (10.1% vs 11% with UFH). There were no significant 
differences in major bleeding at 7 days (Petesern et al., 2004). Enoxaparin was consistently 
beneficial when an early conservative strategy was implemented. The Superior Yield of the New 
Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) 
trial treat UA/NSTEMI patients with an early-invasive strategy taking the primary endpoint 
was all-cause death or nonfatal MI at 30-day follow-up (Ferguson et al., 2004). The primary 
endpoint occurred in 14.5% of patients receiving UFH and in 14% of patients receiving 
enoxaparin (a nonsignificant 3% risk reduction). Enoxaparin therapy was associated with a 
20% increase in TIMI major bleeding in UA/NSTEMI patients undergoing invasive 
procedures, especially CABG procedures. Blazing et al., (2004) showed that the event rates 
in 3,987 patients receiving the GPIIb/IIIa inhibitor tirofiban were similar to those in patients 
receiving enoxaparin and those receiving UFH. The primary endpoint was a composite of 
death, new MI, or refractory ischemia within 7 days. However, the incidence of TIMI major 
bleeding not related to CABG revealed an event rate of 15% in the enoxaparin group 
compared with 4% in the UFH group. Compared with UFH, enoxaparin appears to be superior in 
reducing ischemic events in UA/NSTEMI patients who are treated with early-conservative strategies.  
3.9.3 Factor X (prothrombinase enzyme) inhibitors 
Fondaparinux is a synthetic sulfated pentasaccharide that binds to AT early in the 
coagulation cascade, thereby indirectly inhibiting factor Xa. Its specificity and selectivity, 
combined with its long half-life and 100% bioavailability, enables once-daily anticoagulation 
without the need to monitor the activated clotting time. Fondaparinux inhibits factor Xa 
within the clot itself without inhibiting platelet function, which prevents thrombus 
progression and enhances AT’s effectiveness in a safe manner. The Organization to Assess 
Strategies for Ischemic Syndromes (OASIS) study showed that fondaparinux was 
statistically equivalent to enoxaparin with respect to the primary efficacy endpoint (death, 
MI, or refractory ischemia) at 9 days (5.8% vs 5.7%, respectively). The composite of death, 
MI, refractory ischemia, or major bleeding at 9 days occurred in 7.3% of fondaparinux 
patients vs 9% of enoxaparin patients. The efficacy was maintained for up to six months. 
Major bleeding at 9 days was significantly lower with fondaparinux than with enoxaparin 
(2.2% vs 4.1%). Results from MICHEL-ANGELO OASIS-5 Steering (2005) showed that 
fondaparinux increased the rate of guiding-catheter thrombus formation (29 episodes 
(0.9%]) with fondaparinux vs 8 episodes with enoxaparin (0.3%).  
Bivalirudin is an FDA-approved direct thrombin inhibitor. The Bivalirudin Angioplasty 
Trial (BAT) compared bivalirudin to heparin and found that bivalirudin had superior 
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clinical outcomes in terms of reducing the rate of death, MI, and revascularization (6.2% vs 
7.9% for bivalirudin versus heparin). Also, bivalirudin was associated with a decreased 
frequency of hemorrhage compared with heparin (3.5% vs 9.3%) (Bittl et al., 2001). In a similar 
study (Comparison of Abciximab Complications with Hirulog Ischemic Events Trial 
[CACHET]), bivalirudin plus provisional abciximab was compared with heparin plus planned 
abciximab (Lincoff et al., 2002). Again, bivalirudin had superior clinical outcomes regarding 
death, MI, revascularization, and major hemorrhage at seven days (14.1% vs 3.5% for heparin 
versus bivalirudin). Bivalirudin is addressed in the guidelines as an option for invasive 
management of ACS. It was studied in 6010 low- to moderate-risk patients undergoing urgent 
or elective PCI in the REPLACE-2 trial (Lincoff et al., 2003). In that study, the primary 
composite endpoint (death, MI, urgent repeat revascularization, or in-hospital major bleeding) 
occurred in 9.2% of patients in the bivalirudin group vs 10% of those in the heparin plus GP 
IIb/IIIa group within 30 days of randomization. There was no significant difference between 
bivalirudin alone compared with heparin plus a GP IIb/IIIa inhibitor for the composite 
ischemia endpoint. In addition, bivalirudin alone was shown to have a significantly lower rate 
of major bleeding and reduced rate of the net clinical outcome (Stone et al., 2006).  
3.10 Thrombolytics 
All available fibrin-specific thrombolytic agents have the same general mechanism of 
fibrinolysis. They have the property of fibrin-enhanced conversion of plasminogen to 
plasmin. When introduced into systemic circulation at pharmacologic concentrations, they 
preferentially bind to fibrin in a thrombus and catalyze cleavage of entrapped plasminogen 
to plasmin. This begins local fibrinolysis with limited systemic proteolysis. These agents 
differ from the prototype streptokinase (nonfibrin-specific) in that they enzymatically cleave 
plasminogen to plasmin, whereas streptokinase causes an indirect conformational change in 
the plasminogen molecule, which then acts as plasmin. Examples of these agents include 
alteplase (rt-PA), reteplase (r-PA) and tenecteplase (TNK) which are approved for treatment 
of acute myocardial infarction. As measured by decreases in plasminogen and fibrinogen 
levels, r-PA, rt-PA, and TNK have increasing fibrin specificity. TNK, is a genetically 
engineered variant of rt-PA. Its name refers to the sites of amino acid modification (T103N, 
N117Q, KHRR 296-299 AAAA). This modification is believed responsible for the increased 
fibrin specificity compared with r-PA and rt-PA. TNK has improved resistance to 
inactivation by plasminogen activator inhibitor-1 (PAI-1) compared with rt-PA (Collen et al., 
1994; Keyt et al., 1994). Plasminogen activator inhibitor-1 is an endogenous substance 
capable of rapidly binding and inhibiting both single-chain and two-chain endogenous 
tissue plasminogen activator (t-PA), and similarly inactivates r-PA and rt-PA (Nordt et al., 
1998). Thrombolytic therapy reduced the mortality of patients with acute myocardial 
infarction. Survival benefit is documented with streptokinase, anistreplase, rt-PA, r-PA, and 
TNK. Thrombolysis trials showed thrombolytics to be beneficial in most patients; however, 
approximately 25% of patients eligible for therapy do not receive it, with those at highest 
risk for death least likely to be treated (Barron et al., 1998). The available data showed the 
efficacy fibrin-specific thrombolytic drugs in establishing the patency in an occluded 
coronary artery. These studies were specifically designed to measure patency rates, not 
mortality rates, as the primary outcome. Also r-pA-rt-PA and TNK improve the survival 
rate and provide similar combined mortality benefit after acute myocardial infarction. In all 
trials the most critical adverse event was bleeding. Intracranial hemorrhage occurred at a 
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rate less than 1% with r-PA, rt-PA, and TNK, with higher frequency in patients older than 75 
years. Other noncerebral major bleeding complication requiring blood transfusion occurred 
at a similar rate with r-PA and rt-PA, and was significantly less with TNK. No other adverse 
events have been reported. Unlike streptokinase, rechallenge with fibrin-specific agents does 
not produce an antigenic response. Contraindications for r-PA, rt-PA, and TNK include 
active internal bleeding; intracranial or intraspinal surgery or trauma within 2 or fewer 
months; intracranial neoplasm, arteriovenous malformation, or aneurysm; bleeding 
diathesis; and severe uncontrolled hypertension. Conditions that may increase the risk of 
bleeding (warnings) are recent major surgery (≤ 10 days), cerebrovascular disease, recent (≥ 
10 days) gastrointestinal or genitourinary bleeding, recent (< 10 days) trauma, hypertension 
(≥ 180 mm Hg systolic, ≥ 110 mm Hg diastolic), acute pericarditis, subacute bacterial 
endocarditis, hemostatic defects secondary to severe hepatic or renal disease, significant 
liver dysfunction, pregnancy, retinopathy, current therapy with oral anticoagulants 
(warfarin), and septic thrombophlebitis. Although advanced age (> 75 yrs) increases the risk 
of bleeding, these patients still experience significant benefit from therapy. 
3.11 Angiotensin converting enzyme inhibitors (ACEIs) 
Angiotensin-converting enzyme inhibitors (ACEIs) have been shown to reduce the rate of 
mortality and to prevent cardiovascular events in patients with coronary artery disease, 
especially after acute myocardial infarction (The EUROPA, 2003; Pfeffer et al., 1995). The 
authors of the EUROPA (European Trial on Reduction of Cardiac Events With Perindopril in 
Stable Coronary Artery Disease) study showed a 14% reduction in total rate of mortality, 
nonfatal MI, unstable angina, and cardiac arrest. ACEIs, through the reduction of angiotensin 
II and increased bradykinin availability, explicate their cardioprotective proprieties on left 
ventricular afterload and remodeling, improving cardiac hemodynamics, and reducing 
ventricular mass (Okin et al., 2003). In addition to lowering blood pressure, ACEIs possess a 
vasculoprotective and anti-ischemic action through their antiatherosclerotic, antithrombotic, 
anti-inflammatory effects (Brasier et al., 2002).Long-term treatment with ACE inhibitors after 
myocardial infarction is associated with improved outcomes, especially in patients with left 
ventricular systolic ejection fraction less than 40%. Elderly ACS patients appear to derive 
greater benefit from ACE inhibitors than their younger counterparts. ARBs should be used as 
an alternative in ACE inhibitor intolerant patients. ACE inhibitors and angiotensin receptor 
blockers (ARBs) are not part of the initial management of ACS patients and should not be 
started until the patient is stabilized and is ready for hospital discharge. Renal function and 
electrolytes should be monitored closely, especially in elderly patients. 
3.12 Lipid lowering agents; HMG-Co reductase inhibitors; Statins 
Statins were initially identified as secondary metabolites of fungi. One of the first natural 
inhibitors of HMG-CoA reductase, ML-236B, was isolated as a metabolite from cultures of 
Penicillium citrinum and was shown to be an extremely potent competitive inhibitor of 
HMG-CoA reductase. Statins are either hydrophilic such as pravastatin and rosuvastatin or 
lipophilic statins e.g. atorvastatin and simvastatin. The beneficial effects of statins extend to 
patients regardless of age, sex, or baseline cholesterol levels. The pleiotropic (pleiotropy” 
comes from the Greek words pleio, which means many, and trepein, which means 
influencing) effects of statins include:  
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1. Improve endothelial function in patients with hypercholesterolemia and atherosclerosis 
via up-regulating eNOS. 
2. Attenuate cytokine-mediated vascular smooth muscle cell (VSMC) proliferation in 
coronary artery smooth muscle cells and also inhibit pathological proliferation such as 
that observed in transplant-associated arteriopathy 
3. Could inhibit cardiac hypertrophy through an antioxidant mechanism involving 
inhibition of Rac1 geranylgeranylation 
4. Exert protective function against ischemic myocardial injury 
5.  Inhibit platelets aggregation 
6. Modulate immune activation and to exert anti-inflammatory effects on the vascular 
wall by decreasing the number of inflammatory cells in atherosclerotic plaques 
7. Contribute to plaque stability by reducing plaque size or by modifying the 
physiochemical properties of the lipid core 
8. Protect the brain from Alzheimer's dementia 
Statins very effective in the reduction of mortality and non-fatal cardiovascular events rates 
in both primary and secondary prevention of ischemic heart disease. Statins via their 
pleotropic effects inhibit the pathogenic pathways of coronary artery disease. They reduce 
total-and LDL-cholesterol accumulation in plaque, endothelial dysfunction, activation of 
inflammation and thrombus formation. An increasing number of observations demonstrate 
that statins may play a beneficial role not only in early secondary prevention but also 
directly in the therapy of ACS i.e. when statin treatment is started as first-line care in 
clinically unstable patient. The study of Ostadal et al., (2010) failed to demonstrate the 
beneficial effect of fluvastatin as first line therapy in acute coronary syndrome on the serum 
markers of inflammation and plaque instability; C-reactive protein, interleukin 6, 
pregnancy-associated plasma protein A (PAPP-A/proMBP). Statins is the most efficacious 
therapies for patients with established coronary disease, and evidences suggest that these 
agents are beneficial in the setting of ACS. Intensive lipid-lowering therapy reduces adverse 
clinical events, including death and MI, compared with moderate-dose therapy in patients 
with acute coronary syndrome (de Lemos et al., 2004). The best recognized and most 
commonly reported adverse effects of statins are muscle adverse effects and include muscle 
pain, fatigue and weakness as well as rhabdomyolysis. Fibrates, particularly gemfibrozil, 
amplify the risk of rhabdomyolysis on statins (most powerfully for cerivastatin), due to their 
effect of impeding statin metabolism and perhaps their additional lipid-modifying effects. 
Concurrent administration of statins with CYP3A4 inhibitors (e.g. cyclosporine, erythromycin, 
azole antifungal and antiretrovirals such as ritonavir.) may raise statin concentrations and risk 
of toxicity, including rhabdomyolysis. Grapefruit juice and perhaps pomegranate juice inhibit 
CYP3A4 and have been presumptively linked to statin rhabdomyolysis. Non muscle statin 
adverse effects include cognitive problems, gastrointestinal and neurological symptoms, 
psychiatric symptoms, sleep problems, glucose elevations. 
4. Miscellaneous 
Perhexiline has been used as an antianginal drug since the early 1970s (Armstrong et al., 
1974) when its mode of action was thought to be via coronary artery vasodilatation mediated 
by calcium channel antagonism (Opie, 1980). Perhexiline is now thought to exert its anti-
anginal action primarily by inhibiting the enzyme carnitine palmitoyltransferase (Kennedy 
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et al., 1996). This inhibition reduces fatty acid metabolism in favour of carbohydrate 
metabolism which increases available energy for the same amount of oxygen. Perhexiline is 
relatively free of negative inotropic effects and does not increase airways resistance and is 
therefore not contraindicated in such situations. Perhexiline has been shown to be superior 
to ǃ-adrenoceptor blockers in its ability to reduce the frequency of anginal attacks and in 
addition, because it has a different mode of action, it provides additional antianginal benefit 
when added to existing agents (Stewart et al., 1996). Its use declined in the mid 1970s 
(Horowitz, 1995) because of the occurrence of severe adverse effects during long-term 
therapy including neuropathy and hepatotoxicity (Cooper et al., 1985). The incidence of 
these adverse effects was noted to be related to plasma perhexiline concentration and it was 
observed that adverse effects could be prevented if plasma concentrations were kept below 
defined values (Pilcher et al., 1985; Horowitz., 1986). 
l-carnitine 
L-carnitine is a naturally occurring amino acid essential for the transport of fatty acids into 
the mitochondria. It involved in oxidation of long-chain fatty acids and stabilization of 
cellular membranes and is also a free-radical scavenger. Skeletal and cardiac muscle use 
fatty acids as main source of energy, therefore, carnitine deficiency mainly manifests as 
dysfunction of the above tissues. Carnitine depletion can also cause hypoglycemia, 
hyperammonemia, hypoketonemia, coma, seizures, and developmental disorders. Cardiac 
muscle contains very high levels of carnitine compared with other tissues. Myocardial 
ischemia has been shown to deplete carnitine levels in the myocardium. When combined 
with elevated levels of fatty acids during ischemia, this leads to elevation of toxic 
metabolites of fatty acid esterification. It has been suggested that depletion of free L-
carnitine in the ischemic myocardium can impair the electrical and contractile activities of 
the heart. Carnitine may make cardiomyocytes more resistant to free radicals. Another 
proposed mechanism is through shifting the metabolism from fatty acid oxidation to 
glucose oxidation. Propionyl L-carnitine (PLC) is a carnitine derivative that may have 
enhanced beneficial effects compared with carnitine. Carnitine significantly reduced left 
ventricular end-diastolic, end-systolic pressures, and infarct size in patients presenting with 
acute myocardial infarction and reduced the mortality rate from heart failure (Iliceto et al., 
1995; Singh et al., 1996). In patients with chronic stable angina, carnitine improved exercise 
tolerance; significant improvements in exercise duration and time needed for ST-segment 
changes to return to baseline (Iyer et al., 2000). 
Ribose 
Ribose is a pentose sugar that has been shown in numerous animal experiments to 
enhance ATP production and improve cardiac function. Ribose can enhance metabolism 
by entering the pentose phosphate pathway and bypassing the rate limiting enzymes  
of glucose-6-phosphate dehydrogenase and 6-phosphogluconate-dehydrogenase. It 
improves the time to ST-segment depression and time to moderate angina, and diastolic 
relaxation by restoring ATP levels (Pliml et al., 1992). Ribose supplementation improves 
diastolic heart function, increases exercise tolerance and enhances patient quality of life. 
These benefits are provided by the role ribose plays in increasing cardiac energy reserves 
that become depressed during ischemia or hypoxia associated with coronary artery 
disease or congestive heart failure. 
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Dichloracetate (DCA) 
Dichloroacetate (DCA) can overcome fatty acid inhibition of glucose oxidation by 
stimulating the pyruvate dehydrogenase complex, the rate-limiting enzyme for glucose 
oxidation (Stacpoole et al., 1998). By this effect, DCA enhances contractile function during 
reperfusion and significantly improves cardiac efficiency. The beneficial effect of DCA in 
ischemia-reperfusion injury may be attributed to: 
1. DCA reduces the proton production from glucose metabolism. This was associated with 
an increase in the rate of intracellular pH recovery as well as in improvement in cardiac 
efficiency (Liu et al., 1999).  
2. DCA may exert its beneficial effects by influencing mitochondrial proton leak. Proton 
leak occurs when proton motive force is consumed without ATP synthesis (Brand et al., 
1994). 
In clinical studies, DCA has been shown to increase left ventricular stroke volume in 
patients with coronary artery disease and dramatically improve recovery of cardiac work 
following ischemia. DCA improves acidosis in critically ill patients and, likewise, improves 
myocardial hemodynamics in those with chronic coronary artery disease and congestive 
heart failure; however, its metabolism is variable and clinical data on its use in chronic 
ischemic heart disease are limited (Schofield and Hill, 2001). The use of DCA is limited by its 
low potency (blood levels need to approach millimolar levels) and short half-life. 
Glucose Insulin Potassium (GIK) 
Glucose-insulin-potassium (GIK) therapy is one of the most widely investigated approaches 
used in a clinical setting; it was first reported in 1962 with results from new trials continuing 
to be published. In the 1960's Sodi-Pallares refined the treatment by adding insulin and 
potassium to the infusion, and demonstrated that the treatment was effective for the 
arrhythmias and angina (Sodi-Pallares et al., 1962; 1963).   
The beneficial effects of hyperglycemia and hyperinsulinemia could be due to: 
1. An increase glycolytically derived ATP 
2. An increase in pyruvate dehydrogenase enzyme activity due to decreased plasma 
FFA concentration and elevated insulin levels, resulting in less lactate and H+ 
accumulation 
3. Less accumulation of noxious fatty-acyl CoAs due to lower FFA levels.  
Glucose and insulin infusion was also decrease infarct size and prevent the fall in creatine 
phosphate, ATP and pH in animal models of ischemia/reperfusion injury (Maroko et al., 
1972; Opie and Owen, 1976). Clinical trials with glucose and insulin infusion following 
myocardial infarction) or coronary artery by-pass surgery (Gradinak et al., 1989) have 
generally been favorable. Although in general GIK therapy is found to improve outcome 
after acute myocardial infarction, this is not a uniform observation (Pache et al., 2004). The 
most frequently mechanism underlying the protection associated with increased myocardial 
glucose use are that it improves efficiency by decreasing oxygen consumption and improves 
the coupling between glucose oxidation and glycolysis, thereby reducing intracellular 
acidosis (Liu et al., 2002). Glucose and insulin infusions have been used to raise glycogen 
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levels prior to cardiac surgery. In general, an infusion of glucose and insulin results in 
hyperglycemia (>10 mM), hyperinsulinemia (>80 μU/ml), and low plasma FFA levels (<0.3 
mM) (Wisneski et al., 1990). Hyperglycemia and hyperinsulinemia result in an increase in 
glycogen synthesis. Studies in patients have shown that infusing glucose and insulin 
overnight prior to cardiac surgery results in a 50–70% increase in cardiac glycogen 
concentration and improved clinical outcome from cardiac surgery (Berggren et al., 1982). 
Coronary-artery-bypass graft patients with elevated preoperative myocardial glycogen 
levels had reduced serum levels of myocardial enzymes during the post-operative period 
and a lower incidence of arrhythmias.  
Etomoxir 
Etomoxir (ethyl 2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate) is an inhibitor of 
carnitine palmitoyltransferase I enzyme (CPT I). It is of potential interest in the treatment of 
diabetes since inhibition of fatty acid oxidation should increase glucose utilization and 
decrease gluconeogenesis. By inhibiting fatty acid oxidation, fatty acid-induced inhibition of 
glycolysis may be overcome, thereby increasing glucose utilization. As a result of inhibition 
the CPT I the myocardial fatty acid oxidation is reduced and thereby relieves fatty acid 
inhibition of pyruvate dehydrogenase enzyme activity, and increases the oxidation of 
glucose and lactate. This has anti-ischaemic efficacy and improves cardiac function during 
the recovery from ischaemia. However, long-term administration of such agent has been 
found to be associated with toxicity problems, and in particular their causing cardiac 
hypertrophy (Rupp et al., 1995). In experimental animal model, etomoxir does not affect 
ventricular mass in rats with left ventricular hypertrophy following aortic banding, and 
actually prevents the impairment in contractile function in this model.  
Diazeniumdiolates (NONOates) 
The first of this class was diethylamine NONOate; DEA/NO synthesized in 1960. However, 
Diazeniumdiolates only became the focus of attention in the NO world in the 1990s when 
their NO donor properties were considered in biological settings (Maragos et al., 1991). An 
attractive feature of this class of compounds is that their decomposition is not catalysed by 
thiols or biological tissue, unless specifically designed to (see below) and, because NO 
release follows simple first-order kinetics, the rate of NO release can be accurately predicted. 
Subsequently, biological activity such as vasodilatation, inhibition of platelet aggregation, 
inhibition of blood coagulation and inhibition of VSMC proliferation closely correlate with 
the amount of NO generated in vitro. At present, NONOates not used clinically, although 
they have been tested frequently in experimental models of cardiovascular disease. The 
primary cardiovascular focus for NONOates has been in the prevention of thrombosis and 
neointimal formation following vascular injury, an inevitable result of interventional 
cardiology techniques, such as balloon angioplasty, bypass grafting or placement of stents. 
S-Nitrosothiols 
The S-nitrosothiol class of NO donors covers a vast array of different compounds which 
contain a single chemical bond between a thiol (sulphydryl) group (R-SH) and the NO 
moiety. Biological activity of S-nitrosothiols is highly influenced by the molecular 
environment of the parent thiol. It is important to acknowledge that a vast number of factors 
are capable of releasing NO from S-nitrosothiols, including light, heat, transition metals, 
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thiols, superoxide and enzymes such as xanthine oxidase, superoxide dismutase, protein 
disulphide isomerase and various dehydrogenases. S-nitrosothiols have advantages over 
other classes of NO donors, such as the nitrates, as they have far less stringent metabolic 
requirements and this may be the reason that they do not induce tolerance with long-term 
use (Hanspal et al., 2002). S-Nitrosothiols are not used clinically at present, but there are a 
large number of animal and clinical studies demonstrating their advantageous features, 
especially in the cardiovascular system.  
Plants, herbs, and other natural resources  
Several studies reported that some herbal medicines exert an effect on hemodynamic 
function in human. The effect of these natural plants and herbs are either directly or 
indirectly via their antioxidant properties. The use of such remedies is not free from serious 
adverse effect as well as adverse interactions with other drugs prescribed in acute coronary 
syndrome. The followings are the most common natural substances that exert certain 
pharmacological actions on the cardiovascular system.  
Hawthorn 
It also known as Crataegus laevigata or Crataegus monogyna, is an herb commonly found 
in Europe, western Asia, North America and North Africa. Modern medicinal extracts 
usually incorporate the leaves and flowers of the hawthorn tree, whereas traditional 
preparations use the fruit. Parts of the hawthorn tree contain flavonoids, which decrease the 
likelihood of blood vessel damage. Consuming hawthorn extract may improve angina 
patients' heart function and ability to exercise. It has been used for cardiac and circulatory 
disorders since the first century AD (Weihmayr and Ernst, 1996). Hawthorn berries, flowers 
and leaves of Crataegus laevigata (Poiret) have been used traditionally throughout Europe to 
treat cardiovascular diseases including hypertension, myocardial dysfunction, angina and 
tachycardia (Mills and Bone, 2000). In France, it is also used for insomnia and anxiety 
(British Herbal Medicine Association, 2003). Twentieth century German research revealed 
the efficacy of hawthorn for the treatment of cardiac failure (Pittler et al., 2003), and it is for 
this use that hawthorn is best known. The ethanolic extract of Crataegus oxycantha (COC) is 
traditionally used as a cardiotonic in China, India, and many European countries. COC 
contains oligomeric proanthocyanidins, flavonoids, and polyphenols which are well-known 
for their antioxidant properties (Svedstrom et al., 2002). Human subjects treated with COC 
extract after myocardial infarction have shown improvements in heart rate, reduction in 
blood pressure, and an increase in the left-ventricular ejection volume (Degenring et al., 
2003; Walker et al., 2002). It has also been shown that an alcoholic extract of COC promoted 
improvement in tricarboxylic acid (TCA) cycle enzyme activity and protected the 
mitochondria against isoproteronol-induced cardiac injury (Jayalakshmi and Devaraj, 2004; 
Jayalakshmi et al., 2006). Recently COC extract may reduce the oxidative stress in the 
reperfused myocardium of isolated rat heart preparation, and play a significant role in the 
inhibition of apoptotic pathways (via upregulating the antiapoptotic proteins and 
downregulationg the proapoptotic proteins) to cardioprotection (Swaminathan et al.,2010). 
Hawthorn demonstrated numerous properties that may be beneficial in heart failure 
including anti-arrhythmic activities (Garjani et al., 2000; Chatterjee et al., 1997), and the 
ability to increase coronary blood flow (Occhiuto et al., 1986 (a,b), and cardiac output 
(Brixius et al., 1998). These effects may be mediated by inhibition of phosphodiesterase types 
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III and IV (Schussler et al., 1995), antioxidant activities (Bahorun et al., 2003) and anti-
inflammatory effects (Chatterjee et al., 1997). A meta-analyses of clinical trials concluded 
that hawthorn may be a safe and effective treatment for chronic heart failure (Pittler et al., 
2003). Crataegus extract (hawthorn), raises intracellular calcium, prolongs the action 
potential, and may improve exercise capacity in mild heart failure. It is widely used in 
Europe by heart failure patients as a “natural” remedy. Hawthorn contains no cardioactive 
glycosides. The principle active components are flavonoids: non-toxic phytochemicals that 
are widespread in fruit and vegetables and that have health benefits. It showed low toxicity 
in animal studies and minimal side effects in clinical trials (Mills and Bone, 2005). No drug–
herb interaction has been reported in animal trials, and in a human study no interaction was 
observed between hawthorn and digoxin (Tankanow et al., 2003). Herbal practitioners use 
hawthorn for cardiovascular dysfunction, including mild manifestations in otherwise 
healthy people, without restriction on long-term use. 
Cactus 
Cactus (Opuntia) has been used for many years as a common vegetable and as medicine by 
the Native Americans and Mexicans (Cornett, 2000; Kay, 1996; Knishinsky, 1971; Tesoriere et 
al., 2004). Cactus contains a fruit known as cactus pear (Opuntia ficus-indica) and the plant is 
referred to as nopale (pad). Cactus pear contains pectin, carotenes, betalains, ascorbic acid, 
quercetina and quercetin derivatives all of which have antioxidant activity (Wang, 1988). In 
Chinese medicine, cactus fruit is considered a weak poison and used as medicine for 
treatment of inflammation and pain. It has also been used as a detoxification agent for snake 
bite. Opuntia ficus indica supplementation induced changes in heart rate variability in 
athletes in terms of increasing high and low frequency activities and reducing the heart rate 
(Schmitt et al., 2008). Cactus, also known as Selenicereus grandiflorus, may be effective for 
treating angina. Cactus can be used as a diuretic, cardiac stimulant and spinal and motor 
nerve stimulant. The principle action of cactus is upon the circular muscle fibers of the heart 
and arterioles, or tiny arteries, and that cactus is beneficial for cardiac incompetence, 
congestive heart failure, cardiac weakness, mitral insufficiency and angina. The succulent 
stem is the part of the cactus used for treating heart-related conditions. Overdose may cause 
arrhythmias, chest pain, pericarditis, confusion, headaches, vertigo and gastrointestinal 
symptoms.  
Ammi visnaga (Khella, Khillah) 
Khella, also known as Ammi visnaga, may help treat angina. Khella is an African plant that 
contains spasm-relieving compounds, including khellin. In early studies, purified khellin 
demonstrated an ability to relieve angina-related symptoms, although it is unknown 
whether the whole herb would have similar effects. Khella improves blood supply to the 
myocardium, and increases efficiency of myocardial metabolism--two factors that could 
decrease angina-related pain or discomfort. Khella is often used to treat mild forms of 
angina, mild obstructive pulmonary disease and various problems of the urinary tract. As 
early as 1945 Anrep et al., demonstrated in physiological experiments that khellin is an 
effective coronary vasodilator in doses insufficient to cause any general fall in blood 
pressure. And in the preliminary clinical trial khellin has advantages over the nitrites and 
other reputed vasodilators in that it has a selective action on the coronary vessels, and 
effective doses need not, therefore, lower systemic blood pressure. Its action is slower but 
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more prolonged than that of the nitrites. It may be given in the form of continuous treatment 
to abolish or reduce the frequency and severity of anginal attacks, or to relieve individual 
severe attacks of pain. 
Vaccinium myrtillus (Bilberry) 
It is a member of the Ericaceous family found in the mountains and forests of Europe and 
North America. Vaccinium myrtillus extracts (VME) contained 15 different anthocyanins 
which possess potent antioxidant properties, stabilize collagen fibers, promote collagen 
biosynthesis and inhibit platelet aggregation. In experimental animal studies VME have 
demonstrated to be of benefit in improving vascular tone, blood flow and vasoprotection 
(Lietti et al., 1976; Colantuoni et al., 1991). In isolated rat heart preparation bilberry extract 
increases the coronary flow, decreases the lactic dehydrogenase enzyme release during 
reperfusion and shorten the duration of arrhythmias (Žiberna et al., 2009).  
Co-Enzyme Q10  
Coenzyme Q10 (CoQ10) is the predominant human form of endogenous ubiquinone. It 
synthesized in the mitochondrial inner membrane. CoQ10 and comprised of a ubiquinone 
head group attached to a tail of 10 five-carbon isoprenoid units that anchors the molecule to 
the mitochondrial membranes. It acts in the in the mitochondrial respiratory chain as 
electrons carrier from complex I and II to complex III. It is antioxidant and plays a role in the 
regulation of membranes physiochemical properties and modulates the endothelial 
function. Supplemental CoQ10 is known to reduce lipid peroxidation (Sugiyama et al., 1980). 
Good evidence supports its use in congestive heart failure, type 2 diabetes, atherosclerosis, 
migraine, and Parkinson disease (Bonakdar and Guarnieri, 2005). Coenzyme Q10 levels are 
reduced by statin therapy because it shares the hepatic mevalonate synthetic pathway with 
cholesterol (Jula et al., 2002). Patients with hypertension have reduced serum levels of CoQ10 
(Yamagami and Shibata, 1975). A meta-analysis of 12 clinical trials of 352 patients concluded 
that CoQ10 lowers blood pressure therefore it would seem acceptable to add CoQ10 to 
conventional anti-hypertensive therapy (Rosenfeldt et al., 2007). CoQ10 supports the 
production of energy in the heart and supports the health of the cardiac muscle.  
Zingiber officinale (Ginger) also strong antioxidants that support the health of the blood 
vessel and help protect the heart and vessels from the damage of free radicals. It reduces the 
levels of triglycerides and low-density lipoprotein-cholesterol, and inhibits the blood 
platelet aggregation. The pharmacologic cardiac effects of ginger are based on its activity as 
hypolipemic agent, anticoagulant and hypotensive. 
Allium sativum (Garlic)  
The health benefits of garlic have been known since at least 1500 B.C. when ancient Chinese 
and Indians used it as a blood-thinning agent. Hippocrates, the father of modern medicine, 
used garlic to treat cervical cancer. Subsequent studies found efficacy of garlic as a 
cardioprotective. Numerous studies documented the hypoglycemic, antiatherogenic and 
antiatherosclerotic properties of garlic (Elkayam et al., 2003; Agarwal, 1996; Banerjee and 
Maulik, 2002). Garlic was also found to be beneficial against ischemic heart disease (Tyrrell. 
1979). A significant number of clinical trials found garlic to lower total as well as LDL 
cholesterol (Kwon et al., 2003) and recently it is useful for lowering high blood pressure 
(McMahon and Vargas, 1993). Many of the physiological effects of garlic are attributed to 
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the volatile sulfur compounds like thiosulfinates, which are also responsible for its pungent 
aroma. Recently, the cardioprotective ability of garlic was attributed to s-allylcysteine 
(Perez-Severiano et al., 2004). Blood pressure reducing properties of garlic have been linked 
to its hydrogen sulphide production and allicin content – liberated from alliin and the 
enzyme alliinase which has angiotensin II inhibiting and vasodilating effects, as shown in 
animal and human cell studies. Bhatti et al (2008) demonstrated that garlic extract 
exaggerated the cardio protection offered by ischemic preconditioning and per se treatment 
with garlic extract also protects the myocardium against ischemia reperfusion induced 
cardiac injury. This effect is probably attributed to the inhibition of platelet aggregation, 
oxidative stress or to fibrinolytic properties. 
Arjun (Terminalia arjuna) has demonstrated great promise for improving heart function and 
reducing angina. Arjun (Terminalia arjuna) is a tree common in Central and South India. Its 
bark has a long history of use in Ayurvedic medicine (the traditional medicine of India) for 
the treatment of heart problems, such as angina. Research demonstrates that arjun may in 
fact be very effective in reducing angina and improving heart function. A one-week, double-
blind, placebo-controlled crossover trial of 58 people evaluated the effectiveness of arjun for 
angina by comparing it against placebo, isosorbide mononitrate (Bharani et al., 2002). The 
results indicated that the herb reduced anginal episodes and increased exercise capacity. A 
subsequent 3-month study compared the effectiveness of arjun against placebo in 40 people 
with a recent heart attack (Dwivedi et al., 2005). All participants in this study suffered from 
ischemic mitral regurgitation. The results showed that use of the herb improved heart 
function and reduced angina symptoms. Another study found benefits with an Ayurvedic 
herbal combination containing arjun (Antani et al., 1990).  
Coleus forskohlii 
Coleus forskohlii (CF) is a plant native to India. Since ancient times, plants of the Coleus 
species have been used as an herbal medicine to treat various disorders of the 
cardiovascular, respiratory, gastrointestinal, and central nervous systems. Forskolin has 
been isolated from the roots of the India-based Coleus Forskohlii. Forskolin is a diterpene that 
acts directly on adenylate cyclase leading to generate cAMP from ATP in the cell. cAMP 
regulates the body's thermogenic response to food, increases the body's basal metabolic rate, 
and increases utilization of body fat and stimulates lipolysis. cAMP stimulates the cardiac 
muscle and dilates the large blood vessels. 
Vitamins 
Ascorbic acid 
It has a favorable redox couple that protects vitamin E and glutathione from oxidation. In 
clinical studies, ascorbic acid supplementation improves nitric oxide-dependent 
vasodilation in human subjects with coronary artery disease, hypertension, 
hypercholesterolemia, and diabetes mellitus (Taddei et al., 1998). 
Vitamin E (alpha-tocopherol) 
Vitamin E is a lipid soluble, chain-breaking radical scavenger family of eight related 
tocopherols and tocotrienols, and is considered the most important antioxidant in cell 
membranes (Herrera and Barbas, 2001). Of the various forms, alpha-tocopherol has the 
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highest bioavailability and protects cell membranes against oxidation by reacting with lipid 
radicals produced during lipid peroxidation chain reactions (Herrera and Barbas, 2001). 
Despite an initial small study demonstrating a therapeutic benefit of vitamin E on reducing 
non-fatal myocardial infarction, more recent, placebo-controlled, large-scale trials of 
antioxidants have been disappointing and have found no clinically benefical effects of long 
term vitamin E supplementation (Brown et al., 2001; Lonn et al., 2005). 
Vitamin D 
Recently data demonstrated that vitamin D insufficiency/deficiency is significantly 
associated with all-cause mortality, at least in the American population. The NHANES III 
database clearly shows: 1) an increase in adjusted all-cause mortality as the serum 25-
hydroxy calciferol (OHD) level falls to less than 30 ng/ml, especially in women; and 2) peak 
protection from death with a 25OHD level in the 35–40 ng/ml range. In fact, most of the 
increase in all-cause mortality can be attributed to cardiovascular disease deaths in this 
population. The prevalence of coronary artery disease, heart failure, and peripheral artery 
disease is significantly increased in a stepwise fashion as the serum 25OHD level drops to 
less than 30 and then 20 ng/ml (Kim et al., 2008). 
Omega-3 polyunsaturated fatty acids 
As early as 1944, Sinclair described the rarity of CHD in Greenland Eskimos despite their 
consumption of diet high in fat and cholesterol (Sinclair, 1953). Sinclair observed that the 
Eskimos had a tendency to bruise and to bleed easily, and subsequently Bang and Dyerberg 
demonstrated that the Eskimos had reduced platelet counts (50 000–80 000/mm3 lower) and 
decreased platelet aggregation, resulting in prolonged bleeding times. Bang and Dyerberg 
(1972;1980) and Dyerberg et al.,(1975) in their study comparing Greenland Eskimos and 
Danish controls, found, as expected, that the Eskimos, who eat about 500 g of fish per 
person per day (compared with 10–20 g/d in Westernized societies), had considerably 
higher levels of omega-3 fatty acids and lower levels of arachidonic acid in plasma, platelets, 
and red blood cell membranes. Interestingly, in addition to reduced rates of coronary heart 
disease, the Greenland Eskimos also had a more favorable lipid profile and low levels of 
blood pressure. Coronary heart disease is also less prevalent in Japan, despite higher 
prevalence of hypertension and smoking, which may be partly due to the Japanese 
population's traditionally high consumption of fish compared to populations in the Western 
world. Even within Japan, the Japanese islanders, who eat three times more fish compared 
to the mainland population, have lower rates of hypertension, coronary heart disease, and 
all-cause mortality (Lavie et al., 1987; Lavie and Milani, 1996). The mechanism of actions of 
Omega-3 PUFA includes: 
1. Significant reduction of triglycerides. 
2. Antiarrhythmic effect. The level of long-chain n-3 fatty acids was significantly and 
inversely related to the risk of sudden coronary death  
3. Significant reduction in mean blood pressure, systemic vascular resistance, 
4. Omega-3 fatty acids may confer cardioprotection in part by improving autonomic 
sympathovagal balance. 
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5. Very high doses of omega-3 fatty acids (i.e. 8 g/d) provide anti-inflammatory effects. 
The anti-inflammatory properties may also play an important role in stabilization of 
unstable plaque in patients with ACS (Lee et al., 2008; Alaswad et al., 2002). 
Eicosapentaenoic acid competes with arachidonic acid for the cyclooxygenase, leading 
to decrease the synthesis of thromboxane A2, which is a strong platelet agonist, and 
increases the synthesis of thromboxane A3, which is relatively inactive, so the net effect 
of high doses of omega-3 fatty acids is platelet inhibition. 
Observational studies have also reported inverse associations of cardiovascular disease with 
dietary intake or plasma concentrations of omega 3 fatty acids (mainly eicosapentanoic acid 
and docosahexaenoic acid), suggesting that supplementation with omega 3 fatty acids might 
exert protective effects on cardiovascular disease (Bucher et al., 2002; Kromhout, 1985). 
These fatty acids have been shown to have beneficial effects on several cardiovascular risk 
factors—including blood pressure, plasma triglyceride concentration, and markers of 
thrombosis and inflammation—and may also have antiarrhythmic effects (Wang et al., 
2006). Although some trials involving patients with a history of cardiovascular diseases or 
with high levels of cardiovascular risk factors have reported positive effects of omega 3 fatty 
acids on cardiovascular events, other trials have reported no effects on arrhythmia or 
mortality (Brouwer et al., 2009; Burr et al., 2003).  
5. Cardiovascular adverse effects of herbal remedies 
Several natural remedies interact with known pharmacological agents that indicated in 
acute coronary syndrome. Among these:  
Aloe vera may cause hypokalemia and inducing digitalis toxicity and cardiac arrhythmias 
in patients with heart failure 
Butcher’s broom is mainly indicated for circulatory disorder and it reduced the effect of ǂ-
adrenoceptor effects in patients with hypertension and heart failure 
Capsicum which is indicated for shingles, trigeminal and diabetic neuralgia may elevate the 
blood pressure in patients treated with monoamine oxidase inhibitors 
Fumitory used as hypotensive agent and enhances the effects of ǃ-adrenoceptors, calcium 
entry blockers and glycosides. 
Ginseng causes high blood pressure 
Gossypol, a male contraceptive increases the effect of diuretics and causes hypokalemia  
Grape fruit juice augments the cardiac effects of calcium entry blockers 
Hawthorn potentiates the actions of glycosides and nitrite 
Irish moss potentiates the antihypertensives effects 
Kelp increases the effects of antihypertensives 
Khella increases the cardiac actions of calcium entry blockers 
Licorice increases the blood pressure and causes hypokelemia which potentiates the  
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Lily of the valley increases effects of ǃ-aderenoceptor, calcium entry blockers, digitalis and 
quinidine 
Ma-huang (ephedra) increases heart rate and blood pressure 
Oleander increases the effect of angiotensin converting enzyme inhibitors, antiarrhythmics, 
ǃ-adrenoceptor blockers, calcium entry blockers and cardiac glycosides. 
St. John's wort induces arrhythmias, heart block, hyperkalemia and death 
Strophanthus increases heart rate and blood pressure in patients treated ith monoamine 
oxidase inhibitors 
Yohimbine increases heart rate and induces changes in blood pressure 
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